academi
clinic
laboratori
physician
scientist
aclp
establish
paul
e
strandjord
young
investig
award
program
encourag
student
traine
laboratori
medicin
consid
academ
career
year
call
abstract
sent
member
invit
submiss
scientif
paper
submit
abstract
peer
review
committe
aclp
member
select
confidenti
director
young
investig
program
neal
lindeman
md
review
blind
author
institut
young
investig
award
recipi
grant
free
registr
annual
meet
reimburs
portion
travel
expens
opportun
present
scientif
work
audienc
peer
mentor
follow
abstract
present
lab
medicin
annual
meet
aclp
may
may
san
francisco
ca
author
receiv
young
investig
award
mark
asterisk
aclp
abstract
publish
american
journal
clinic
patholog
ajcp
receiv
aclp
without
ajcp
editori
involv
content
typograph
error
inconsist
abstract
respons
abstract
author
abnorm
b
lymphoid
blast
may
alway
indic
acceler
blast
phase
chronic
myelogen
leukemia
cml
lori
soma
cheng
ding
sindhu
cherian
univers
washington
seattl
wa
object
determin
cml
patient
abnorm
b
lymphoid
blast
ablb
flow
cytometr
studi
fc
progress
acceler
phase
blast
crisi
method
univers
washington
hematopatholog
databas
search
patient
report
posit
molecular
studi
patient
diagnosi
abnorm
immatur
b
cell
popul
fc
report
white
cell
patient
histori
evalu
clinic
present
blast
transform
therapi
outcom
fc
dotplot
review
assess
abnorm
phenotyp
ablb
percentag
ablb
white
cell
fc
histolog
examin
bone
marrow
perform
includ
immunohistochem
stain
ihc
tdt
result
search
criteria
yield
total
entri
five
patient
found
cml
ablb
report
less
viabl
white
cell
fc
peripher
blood
bone
marrow
specimen
initi
present
patient
age
rang
year
includ
three
men
two
women
upon
review
data
ablb
percentag
fc
rang
total
white
cell
commonli
seen
abnorm
includ
increas
n
increas
n
decreas
slightli
decreas
n
three
patient
demonstr
ablb
fc
andor
ihc
remain
two
less
fc
ihc
three
patient
demonstr
increas
number
interstiti
tdt
cell
well
small
cluster
interstiti
paratrabecular
two
patient
tdtposit
cell
per
cluster
one
patient
treat
hyper
cvad
two
cycl
follow
chronic
phase
remain
four
patient
treat
follow
chronic
phase
cml
patient
aliv
without
molecular
evid
diseas
chronic
phase
without
evid
ablb
month
followup
ablb
seen
diagnosi
diagnost
time
frame
seen
subsequ
fc
analysi
avail
report
subsequ
document
conclus
presenc
ablb
cml
patient
present
consid
isol
determin
diseas
phase
treatment
rapid
detect
activ
cardiac
glycosid
convallatoxin
lili
valley
use
loci
digoxin
assay
kerri
j
welsh
richard
p
huang
jeffrey
k
actor
amitava
dasgupta
depart
patholog
laboratori
medicin
univers
texa
health
scienc
center
houston
houston
tx
object
lili
valley
plant
toxic
anim
human
due
presenc
cardiac
glycosid
convallatoxin
extract
plant
use
herbal
medicin
despit
report
case
toxic
luminesc
oxygen
channel
technologybas
digoxin
immunoassay
loci
digoxin
assay
siemen
diagnost
explor
rapid
detect
convallatoxin
potenti
vitro
bind
convallatoxin
digibind
also
evalu
method
aliquot
drugfre
serum
pool
digoxin
serum
pool
supplement
microlit
amount
lili
valley
extract
nanogram
microgram
quantiti
convallatoxin
follow
measur
appar
digoxin
concentr
use
loci
digoxin
assay
mice
administ
lili
valley
extract
convallatoxin
digoxin
concentr
sera
measur
hour
gavag
aliquot
serum
pool
supplement
convallatoxin
lili
valley
extract
supplement
variou
concentr
digibind
free
appar
digoxin
concentr
measur
result
appar
digoxin
concentr
observ
aliquot
drugfre
serum
pool
supplement
convallatoxin
lili
valley
extract
exampl
appar
digoxin
level
ngml
presenc
ngml
convallatoxin
appar
digoxin
level
also
detect
mice
feed
convallatoxin
herbal
extract
halflif
convallatoxin
hour
bidirect
neg
interfer
lower
concentr
posit
interfer
higher
concentr
convallatoxin
lili
valley
extract
serum
digoxin
measur
use
loci
assay
observ
digibind
capabl
bind
convallatoxin
vitro
presenc
digibind
appar
free
digoxin
reduc
ngml
none
detect
drugfre
serum
pool
supplement
lili
valley
herbal
extract
conclus
loci
digoxin
assay
use
rapid
detect
convallatoxin
digibind
neutral
convallatoxin
vitro
thromboelastographi
suboptim
test
determin
underli
caus
bleed
associ
cardiopulmonari
bypass
kerri
j
welsh
angelica
padilla
amitava
dasgupta
andi
n
nguyen
amer
wahe
depart
patholog
laboratori
medicin
univers
texa
health
scienc
center
houston
houston
tx
object
patient
undergo
cardiac
surgeri
cardiopulmonari
bypass
cpb
high
risk
bleed
coagulationbas
hemotherapi
cbh
servic
clinic
patholog
consult
servic
provid
intraop
manag
coagulopathi
transfus
support
base
predefin
algorithm
patient
undergo
surgeri
cpb
one
test
use
servic
thromboelastographi
teg
test
measur
dynam
clot
format
lysi
goal
investig
compar
teg
standard
coagul
test
patient
activ
bleed
due
cpbinduc
coagulopathi
method
patient
intraop
consult
cbh
servic
may
august
select
inclus
studi
teg
valu
coagul
test
pt
ptt
fibrinogen
ddimer
patient
episod
activ
bleed
attribut
coagulopathi
character
util
teg
predict
postop
bleed
assess
second
analysi
perform
determin
shorten
teg
r
time
associ
thrombot
event
result
pair
teg
standard
coagul
test
avail
patient
episod
activ
bleed
attribut
coagulopathi
patient
normal
teg
valu
three
show
shorten
r
time
abnorm
standard
coagul
test
eighteen
patient
underw
surgeri
cpb
episod
postop
bleed
teg
r
time
ci
clot
index
pt
ptt
collect
cpb
associ
postop
bleed
univari
analysi
pt
independ
associ
postop
bleed
multivari
analysi
teg
patient
aspirin
alon
averag
mm
mm
patient
aspirin
clopidogrel
within
refer
rang
mm
second
analysi
three
patient
normal
teg
four
patient
shorten
r
time
thrombot
event
hospit
p
conclus
teg
limit
util
identifi
underli
caus
activ
bleed
independ
predict
postop
bleed
associ
cardiac
surgeri
compar
convent
coagul
test
teg
identifi
patient
aspirin
clopidogrel
risk
factor
bleed
associ
cardiac
surgeri
shorten
teg
r
time
may
repres
hypercoagul
state
power
versu
manual
bone
marrow
biopsi
retrospect
review
dougla
w
lynch
stephani
l
stauffer
nanci
rosenth
sponsor
matthew
krasowski
univers
iowa
hospit
clinic
iowa
citi
ia
power
bone
marrow
biopsi
system
ps
use
sever
year
littl
data
exist
regard
qualiti
patholog
specimen
obtain
evalu
qualiti
quantiti
aspir
biopsi
specimen
obtain
patient
ps
compar
standard
manual
method
mm
univers
iowa
patholog
laboratori
inform
system
review
patient
underw
bone
marrow
biopsi
perform
oncontrol
bone
marrow
system
mm
total
patient
identifi
specimen
review
dilut
aspir
bone
clot
section
cortic
bonesubcort
locat
aspir
crush
artifact
presenc
skin
presenc
singl
intact
core
biopsi
specimen
length
biopsi
specimen
percentag
evalu
marrow
calcul
length
evalu
marrow
compar
case
use
pair
test
core
biopsi
specimen
obtain
ps
significantli
longer
compar
obtain
mm
vs
mm
p
howev
obtain
mm
evalu
marrow
element
vs
p
mm
superior
patient
length
evalu
marrow
calcul
vs
mm
p
everi
biopsi
specimen
acquir
mm
evalu
marrow
two
core
biopsi
specimen
obtain
ps
none
ps
like
see
cortic
bonesubcort
locat
skin
aspir
artifact
bone
clot
section
also
less
like
see
singl
intact
core
biopsi
specimen
ps
find
show
longer
core
biopsi
specimen
obtain
oncontrol
bone
marrow
system
mm
still
superior
percentag
length
evalu
bone
marrow
analyz
case
studi
illustr
clinic
util
liquid
mass
spectrometri
assess
free
thyroid
hormon
statu
verena
francesco
steven
j
laboratori
medicin
nation
institut
health
bethesda
md
endocrinolog
metabol
virginia
commonwealth
univers
richmond
va
medicin
georgetown
univers
washington
dc
major
routin
clinic
laboratori
perform
free
thyroxin
free
triiodothyronin
measur
immunoassay
ia
platform
valid
analysi
direct
analogu
ia
long
question
assay
affect
chang
bind
protein
concentr
weak
invers
linear
log
relationship
thyroidstimul
hormon
tsh
hypo
hyperthyroid
individu
poor
perform
upper
lower
valu
concentr
rang
liquid
mass
spectrometri
lcmsm
follow
ultrafiltr
sampl
method
previous
describ
gu
et
al
clin
biochem
shown
perform
better
circumst
describ
two
case
tsh
valu
discord
ia
andor
valu
lcmsm
method
analysi
use
better
elucid
thyroid
statu
complex
clinic
scenario
case
man
kaposi
sarcoma
admit
intens
care
unit
ward
initi
result
show
elev
tsh
low
ia
pgml
refer
interv
thyroid
antibodi
neg
patient
commenc
thyroxin
replac
therapi
week
replac
therapi
immunoassay
result
follow
tsh
ia
ngdl
pgdl
remain
low
follow
sampl
treatment
heterophil
block
antibodi
ia
rerun
chang
valu
ms
analysi
result
follow
ngdl
pgml
also
thyroxin
bind
globulin
analysi
reveal
decreas
valu
like
reason
low
ia
result
continu
high
normal
tsh
like
due
sick
euthyroid
syndrom
case
woman
sickl
cell
anemia
primari
hypothyroid
receiv
levothyroxin
replac
therapi
followup
tsh
remain
elev
normal
ngdl
low
total
patient
also
continu
symptom
hypothyroid
lcmsm
result
low
ngdl
low
normal
pgml
levothyroxin
replac
therapi
increas
subsequ
normal
tsh
level
conclus
author
believ
lcmsm
analysi
perform
sampl
discrep
tsh
free
thyroid
hormon
immunoassay
valu
comparison
thromboelastometri
rotem
standard
coagul
test
similar
result
improv
patient
care
michael
rey
benjamin
ramo
kendal
p
crookston
sara
c
koenig
depart
patholog
univers
new
mexico
school
medicin
albuquerqu
nm
thromboelastometri
wide
becom
incorpor
evalu
hemostasi
varieti
clinic
set
despit
increas
popular
use
question
still
remain
regard
correl
standard
coagul
test
appropri
use
studi
two
primari
object
address
assess
correl
specif
rotem
paramet
standard
coagul
test
review
potenti
advantag
rotem
compar
standard
coagul
test
rotem
analysi
perform
wholeblood
sampl
collect
period
thirtyfour
sampl
collect
inpati
outpati
seen
coumadin
clinic
remain
sampl
inpati
follow
rotem
analysi
sent
concurr
routin
coagul
test
ptinr
ptt
fibrinogen
coumadin
clinic
patient
consent
first
draw
sent
routin
coagul
studi
pointofcar
inr
test
perform
second
sampl
per
clinic
protocol
correl
found
maximum
clot
firm
mcf
fibrinspecif
clot
format
fibtem
fibrinogen
level
r
addit
observ
strong
correl
amplitud
minut
fibtem
fibrinogen
level
r
fibtem
highli
predict
final
rotem
measur
fibrinogen
fibtem
mcf
correl
clot
time
ct
extem
inr
r
ct
intem
ptt
r
seen
well
addit
correl
variou
rotem
paramet
standard
coagul
test
specif
rotem
featur
may
promot
improv
patient
care
rapid
turnaround
time
evalu
wholeblood
coagul
oppos
plasmabas
test
abil
view
data
locat
distinct
advantag
addit
rotem
test
gener
expens
standard
coagul
test
improv
patient
care
decreas
overal
cost
may
realiz
target
transfus
therapi
rapid
oper
room
turnov
time
sever
vitamin
defici
mimick
thrombot
thrombocytopen
purpura
joshua
k
cristhiam
kendal
p
sara
c
depart
medicin
univers
new
mexico
school
medicin
albuquerqu
nm
microangiopath
hemolyt
anemia
maha
associ
seriou
condit
includ
thrombot
thrombocytopen
purpura
ttp
hemolyt
urem
syndrom
hu
dissemin
intravascular
coagulopathi
dic
howev
vitamin
defici
present
rare
pseudothrombot
microangiopathi
pseudotma
previous
healthi
man
chronic
alcohol
present
rural
medic
center
histori
confus
fever
chill
exert
dyspnea
dizzi
fatigu
associ
diarrhea
hematochezia
laboratori
result
notabl
platelet
count
hemoglobin
hematocrit
mcv
fl
creatinin
within
normal
limit
peripher
blood
smear
show
mark
schistocyt
presum
diagnosi
ttphu
given
patient
transfus
unit
plasma
transfer
tertiari
hospit
therapeut
plasma
exchang
tpe
test
reveal
decreas
vitamin
level
pgml
normal
rang
repeat
peripher
blood
smear
show
mark
macrocytosi
hyperseg
neutrophil
mark
thrombocytopenia
increas
red
cell
fragment
differenti
diagnosi
expand
includ
pseudotma
secondari
defici
patient
receiv
tpe
total
time
mcg
vitamin
daili
day
platelet
hemoglobin
mcv
clinic
condit
gradual
improv
stool
cultur
test
neg
shiga
toxin
level
drawn
tertiari
hospit
first
tpe
addit
workup
confirm
diagnosi
pernici
anemia
given
presenc
antibodi
although
patient
receiv
unit
plasma
prior
transfer
unlik
pretransfus
level
low
enough
consist
ttp
addit
patient
creatinin
remain
within
normal
limit
throughout
hospit
point
diagnosi
pseudotma
result
vitamin
defici
made
tpe
discontinu
occurr
diarrhea
hematochezia
interpret
consequ
malabsorpt
sever
thrombocytopenia
present
respect
patient
laboratori
data
clinic
condit
continu
improv
discharg
home
vitamin
supplement
characterist
rare
advers
event
fatal
transfusionassoci
anaphylaxi
eric
pampe
p
christoph
garrett
laboratori
medicin
yale
univers
new
ct
patholog
microbiolog
immunolog
vanderbilt
univers
nashvil
tn
anaphylaxi
rare
potenti
catastroph
complic
blood
compon
transfus
use
novel
approach
datamin
publicli
avail
us
food
drug
administr
fda
transfus
reaction
record
yield
rel
larg
aggreg
case
number
sought
investig
gener
characterist
fatal
anaphylact
transfus
reaction
atr
determin
possibl
risk
factor
associ
atr
method
file
freedom
inform
act
foia
request
fda
report
fatal
atr
applic
case
sever
paramet
collect
includ
patient
age
type
product
volum
product
infus
durat
transfus
result
report
fatal
atr
data
avail
major
patient
male
n
median
age
year
rang
year
eight
death
associ
freshfrozen
plasma
ffp
three
attribut
platelet
plt
two
attribut
rbc
median
time
onset
estim
minut
ffp
transfus
minut
plt
transfus
minut
rbc
transfus
volum
blood
product
transfus
prior
symptom
onset
estim
eight
case
median
volum
transfus
ml
ffp
n
ml
plt
transfus
n
ml
rbc
transfus
n
infus
rate
could
estim
eight
case
four
ffp
transfus
median
rate
mlmin
two
plt
transfus
median
rate
mlmin
two
rbc
transfus
median
rate
mlmin
conclus
transfus
recipi
die
atr
report
fda
typic
older
adult
receiv
ffp
work
current
way
determin
whether
infus
rate
case
fatal
ffp
plt
transfus
substanti
faster
standard
practic
foia
request
appear
promis
method
gather
inform
transfusionassoci
event
rare
studi
individu
medic
center
like
evolut
kinas
domain
mutat
chronic
myelogen
leukemia
lymphoid
blast
phase
tlymphoblast
geoffrey
wool
farid
f
chehab
sponsor
enriqu
terraza
depart
laboratori
medicin
ucsf
san
francisco
ca
present
uniqu
case
patient
chronic
myelogen
leukemia
cml
lymphoid
blast
phase
lymphoblast
also
coexist
kinas
domain
mutat
bone
marrow
biopsi
initi
ancillari
studi
perform
outsid
institut
review
ucsf
hematopatholog
kinas
domain
mutat
analysi
perform
ucsf
sanger
sequenc
complementari
dna
forward
revers
orient
peripher
blood
patient
man
present
night
sweat
splenomegali
weight
loss
leukocytosi
wbc
lymphoblast
consist
posit
peripher
blood
fluoresc
situ
hybrid
transloc
qpcr
reveal
major
breakpoint
standard
ratio
marrow
biopsi
specimen
markedli
hypercellular
compris
predominantli
blast
matur
granulocyt
virtual
absent
erythropoiesi
megakaryocyt
mildli
increas
number
predominantli
small
diagnos
mix
phenotyp
acut
leukemia
ph
tlymphoblast
leukemialymphoma
consid
rule
morpholog
immunophenotyp
criteria
patient
start
tki
treatment
develop
recurr
splenomegali
month
later
begun
hypercvad
followup
test
treatment
reveal
continu
highli
elev
burden
kinas
domain
mutat
test
reveal
mix
mutant
allel
burden
codon
without
wildtyp
act
codon
major
allel
ctt
codon
c
correspond
mutat
minor
popul
att
codon
correspond
mutat
thu
like
c
mutat
normal
codon
gave
rise
codon
c
substitut
emerg
codon
kinas
domain
mutat
rare
describ
one
case
ph
blymphoblast
leukemialymphoma
whether
progress
allel
impli
wors
prognosi
alreadi
associ
cml
lymphoid
blast
phase
diseas
unclear
time
summari
except
case
report
patient
rare
cml
tlymphoid
blast
phase
well
kinas
domain
mutat
appear
evolv
poor
prognosi
allel
report
clot
ldl
apheresi
kathryn
mari
jame
nicol
l
depart
medicin
univers
colorado
aurora
co
lowdens
lipoprotein
ldl
apheresi
recommend
treatment
sever
hyperlipidemia
individu
famili
hypercholesterolemia
fh
apheresi
may
treatment
choic
sever
reaction
involv
clot
procedur
well
describ
literatur
case
report
report
case
woman
underw
ldl
apheresi
refractori
fh
ldl
apheresi
done
use
dextransulf
cellulos
dsc
column
kaneka
liposorb
system
kaneka
corpor
japan
first
procedur
serum
valu
total
cholesterol
mgdl
ldl
mgdl
lipoprotein
mgdl
receiv
load
dose
unfraction
heparin
uh
uh
infus
rate
initi
procedur
patient
asymptomat
blood
pressur
bp
slowli
declin
minut
reach
nadir
mm
hg
bolu
salin
improv
bp
mm
hg
minut
blood
tube
lead
filter
start
clot
despit
replac
pressur
valv
separ
column
patient
blood
clot
instrument
minut
addit
bp
drop
mm
hg
systol
despit
repeat
bolus
salin
procedur
stop
process
target
plasma
volum
first
procedur
serum
valu
total
cholesterol
mgdl
ldl
mgdl
lipoprotein
mgdl
twentyon
day
later
patient
underw
second
procedur
second
procedur
serum
valu
total
cholesterol
mgdl
ldl
mgdl
lipoprotein
mgdl
procedur
receiv
increas
load
dose
ukg
uh
follow
infus
rate
patient
develop
clot
procedur
bp
labil
follow
vasovag
episod
get
bedsid
commod
procedur
termin
target
volum
second
procedur
serum
valu
total
cholesterol
mgdl
ldl
mgdl
lipoprotein
mgdl
patient
return
third
fourth
treatment
complet
toler
procedur
well
procedur
given
increas
uh
load
dose
ukg
follow
infus
procedur
conclus
report
case
sever
clot
associ
hypotens
ldl
apheresi
perform
dsc
method
clot
dsc
apheresi
well
describ
literatur
one
case
report
grow
bodi
literatur
role
lipoprotein
atherothrombot
complic
hemostasi
support
possibl
mechan
clot
could
occur
apheresi
theori
consist
case
patient
lipoprotein
level
progress
declin
procedur
although
investig
need
avail
literatur
suggest
higher
anticoagul
dose
apheresi
consid
individu
mark
elev
lp
preval
novel
psychoact
substanc
use
among
stimul
abus
san
francisco
jennif
colbi
alan
h
b
wu
kara
l
lynch
depart
laboratori
medicin
univers
california
san
francisco
san
francisco
ca
novel
psychoact
substanc
np
also
known
design
drug
usual
legal
altern
common
drug
abus
found
brickandmortar
store
well
purchas
internet
np
usag
side
effect
subject
signific
media
coverag
unit
state
populationbas
studi
np
preval
reason
includ
lack
avail
standard
unknown
crossreact
commerci
avail
immunoassay
routin
use
screen
tool
develop
liquid
chromatographyhighresolut
mass
spectrometri
hrm
screen
method
amphetaminelik
np
use
method
determin
preval
np
subset
patient
popul
identifi
substanc
caus
fals
posit
amphetamin
immunoassay
one
major
advantag
hrm
method
acquir
accur
mass
data
untarget
manner
data
process
specif
look
mass
correspond
np
techniqu
known
suspect
screen
allow
us
search
data
np
without
acquir
refer
standard
compound
liquid
chromatographi
method
use
phenomenex
kinetex
column
simpl
gradient
mobil
phase
b
minut
mobil
phase
consist
mmoll
ammonium
format
formic
acid
water
mobil
phase
b
consist
formic
acid
methanol
acetonitril
absciex
qtof
mass
spectromet
collect
fullscan
highresolut
data
precursor
ion
informationdepend
acquisit
simultan
product
ion
spectra
analyz
urin
sampl
posit
immunoassay
screen
amphetamin
determin
posit
rate
compound
includ
amin
np
nineti
percent
sampl
confirm
posit
methamphetamin
confirm
posit
amphetamin
sampl
falseposit
screen
confirm
posit
anoth
drug
includ
trazodon
dextromethorphan
doxylamin
bupropion
approxim
sampl
confirm
posit
known
compound
undergo
test
confirm
ethylamphetamin
methylon
mdma
patient
popul
ultim
found
fewer
sampl
posit
amin
np
low
preval
rate
may
reflect
studi
popul
bia
pool
individu
abus
illeg
stimul
may
differ
pool
would
use
np
studi
indic
np
usag
frequent
within
popul
news
media
might
us
believ
quantit
infliximab
serum
use
surfac
plasmon
reson
kati
l
thoren
kara
l
lynch
alan
h
b
wu
depart
laboratori
medicin
univers
francisco
san
francisco
ca
infliximab
chimer
monoclon
antibodi
target
tumor
necrosi
use
treat
varieti
chronic
autoimmun
disord
therapeut
drug
monitor
infliximab
import
guid
patient
manag
serum
concentr
indic
dose
need
adjust
patient
switch
differ
therapeut
current
test
option
infliximab
howev
limit
use
surfac
plasmon
reson
spr
measur
infliximab
concentr
serum
gener
explor
potenti
use
technolog
clinic
laboratori
spr
experi
perform
proteon
biorad
recombin
human
genway
biotech
immobil
glc
chip
biorad
use
standard
amin
coupl
normal
serum
sampl
spike
known
concentr
infliximab
jannsen
biotech
rang
gener
calibr
curv
infliximabspik
serum
dilut
buffer
inject
immobil
minut
surfac
wash
mmoll
hcl
allow
reequilibr
inject
subsequ
sampl
found
chip
stabl
least
bindingwash
cycl
lower
limit
detect
assay
function
sensit
coeffici
variat
patient
sampl
n
run
use
spr
assay
test
refer
laboratori
n
correl
well
spr
result
addit
patient
comparison
studi
way
use
ilit
infliximab
bioassay
biomonitor
overal
result
demonstr
feasibl
use
spr
measur
infliximab
level
patient
sampl
spr
offer
sever
advantag
method
current
use
measur
infliximab
spr
requir
virtual
sampl
prepar
measur
activ
free
fraction
drug
provid
faster
turnaround
time
measur
made
real
time
techniqu
could
potenti
use
measur
protein
therapeut
futur
express
bcell
acut
lymphoblast
leukemia
dosedepend
effect
vorinostat
kristin
konopka
priya
weerasingh
nghia
nguyen
amitava
dasgupta
robert
e
brown
univers
texa
health
scienc
center
houston
houston
tx
silent
mate
type
inform
regul
homolog
naddepend
histon
deacetylas
block
differenti
inhibit
apoptosi
studi
evalu
express
bcell
acut
lymphoblast
leukemia
ball
patient
sampl
context
gender
age
presenc
chromosom
abnorm
sinc
may
function
therapeut
target
also
assess
effect
histon
deacetylas
inhibitor
vorinostat
suberoylanilid
hydroxam
acid
saha
human
ball
cell
line
ccrfsb
institut
review
board
approv
retriev
bone
marrow
case
ball
databas
juli
juli
follow
world
health
organ
classif
initi
diagnost
case
adequ
materi
includ
exclud
postchemotherapi
case
twelv
case
fulfil
criteria
includ
seven
male
five
femal
age
year
six
pediatr
six
adult
among
patient
six
show
abnorm
chromosom
analys
monoclon
antibodi
appli
bone
marrow
aspir
clot
section
dab
chromogen
signal
detect
score
scale
case
variabl
nuclear
express
weak
stain
major
leukem
cell
case
mild
moder
intens
express
verifi
ccrfsb
cell
immunohistochemistri
also
show
nuclear
stain
dose
respons
kinet
experi
perform
ccrfsb
cell
treat
vorinostat
cell
death
prolifer
determin
light
microscopi
electron
microscopi
picel
death
assay
cell
cycl
apoptosi
assess
flow
cytometri
express
determin
util
immunofluoresc
hour
posttreat
concentr
display
cell
death
respect
light
electron
microscopi
show
cell
undergo
apoptosi
cell
cycl
analysi
reveal
peak
signific
chang
immunofluoresc
experi
display
decreas
express
nucleu
hour
vorinostat
exposur
compar
untreat
control
cell
overal
find
suggest
express
ball
regardless
gender
age
genet
statu
furthermor
found
essenti
equival
favor
eg
hyperdiploid
unfavor
eg
karyotyp
conclud
block
differenti
ball
find
support
use
vorinostat
potenti
therapeut
agent
rotem
case
week
onlin
casebas
educ
intervent
introduct
novel
coagul
test
practic
physician
k
l
j
risan
j
l
sponsor
kendal
crookston
depart
critic
care
medicin
univers
new
mexico
school
medicin
albuquerqu
nm
year
rotat
thromboelastometri
rotem
panel
introduc
academ
level
trauma
tertiari
referr
hospit
rapid
method
assess
patient
coagul
statu
direct
appropri
usag
blood
product
clinician
prior
exposur
rotem
panel
sought
develop
didact
onlin
educ
offer
help
practic
physician
understand
interpret
util
test
educ
curriculum
develop
instruct
clinician
would
order
interpret
rotem
also
increas
awar
util
novel
laboratori
panel
two
separ
group
complet
train
concurr
patholog
facultyresid
critic
careanesthesia
faculti
resid
curriculum
consist
rotem
lectur
given
transfus
medicin
servic
follow
onlin
cours
short
casebas
quizz
detail
answer
provid
pretest
given
prior
lectur
ident
onlin
posttest
administ
end
cours
effect
curriculum
assess
evalu
pretest
vs
posttest
score
overal
particip
weekli
quizz
particip
feedback
clinic
applic
satisfact
train
data
analyz
use
spearman
correl
method
particip
enrol
train
complet
least
one
weekli
quizz
fourteen
particip
complet
eight
weekli
quizz
particip
complet
entir
cours
includ
pre
posttest
due
limit
sampl
size
studi
reach
statist
signific
demonstr
chang
pretest
vs
posttest
score
howev
particip
complet
entir
cours
demonstr
improv
averag
improv
includ
particip
demonstr
improv
correct
answer
per
pre
posttest
particip
respond
satisfact
survey
state
enjoy
program
appli
train
principl
clinic
practic
result
indic
weekli
casebas
quiz
effect
educ
tool
introduct
rotem
panel
establish
peripher
blood
smear
review
criteria
base
interpret
autom
analyz
flag
outpati
cancer
care
set
awet
tecleab
elizabeth
southern
john
mcgovern
ellinor
peerschk
depart
laboratori
medicin
memori
sloan
ketter
cancer
center
new
york
ny
background
outpati
cancer
care
requir
rapid
result
blood
cell
leukocyt
differenti
count
autom
analyz
flag
highli
sensit
presenc
immatureabnorm
cell
impact
manual
review
rate
may
delay
result
report
aim
establish
relev
peripher
blood
smear
review
criteria
flag
autom
differenti
result
patient
popul
treat
solid
tumor
outpati
set
method
autom
cbc
differenti
analysi
perform
analyz
four
separ
outpati
site
flag
sampl
review
microscop
examin
wrightgiemsastain
peripher
blood
film
presenc
blast
nucleat
rbc
nrbc
atyp
lymphocyt
platelet
abnorm
consid
posit
find
patient
popul
observ
left
shiftimmatur
granulocyt
flag
expect
patient
undergo
chemotherapi
exclud
review
present
alon
result
distribut
autom
analyz
flag
occur
alon
combin
abnorm
wbc
scattergram
left
shift
ls
nrbc
atyp
lymphocyt
blast
immatur
granulocyt
ig
platelet
abnorm
trueposit
rate
signific
flag
occur
alon
combin
flag
wbc
abnorm
scattergram
respect
nrbc
atyp
lymphocyt
blast
platelet
flag
wherea
nrbc
flag
show
high
trueposit
rate
remain
flag
present
either
alon
combin
fail
reveal
unexpect
find
peripher
blood
smear
review
includ
flag
platelet
clump
remark
occasion
platelet
clump
fibrin
strand
found
peripher
smear
review
chang
autom
platelet
count
base
find
recommend
releas
autom
platelet
count
greater
equal
regardless
platelet
flag
autom
differenti
cell
count
associ
singl
flag
except
nrbc
flag
combin
lsig
flag
without
blast
andor
atyp
lymphocyt
flag
conclus
measur
reduc
manual
review
rate
data
support
import
appropri
autom
cbc
differenti
flag
interpret
specif
patient
popul
cancer
patient
guid
implement
clinic
relev
manual
review
criteria
enhanc
patient
care
maxim
laboratori
effici
reduc
oper
cost
clinic
valid
customdesign
microarray
assay
diagnosi
hematolog
malign
jess
f
nidhi
susann
urvashi
steven
h
aleksandar
svetlana
sponsor
alan
cytogenet
laboratori
patholog
univers
pittsburgh
medic
center
pittsburgh
pa
classic
cytogenet
analysi
gband
play
critic
role
diagnosi
prognosi
treatment
hematolog
malign
allow
detect
larg
genom
alter
howev
necess
divid
cell
poor
chromosom
morpholog
low
resolut
gband
limit
factor
complet
accur
chromosom
studi
introduct
highresolut
array
includ
compar
genom
hybrid
cgh
singlenucleotid
polymorph
snp
enabl
detect
abnorm
detect
gband
addit
copi
number
variat
loss
heterozygos
loh
group
develop
valid
microarray
assay
clinic
use
diagnosi
hematolog
malign
custom
design
contain
oligonucleotid
cgh
probe
cgh
snp
probe
averag
genom
resolut
kb
addit
enhanc
resolut
span
gene
involv
oncogenesi
total
specimen
patient
diagnos
hematolog
malign
aml
four
md
four
ball
three
cll
two
cml
two
pcm
one
pv
analyz
cgh
cgh
snp
array
compar
gband
fish
result
complet
concord
result
gbandingfish
microarray
analysi
observ
five
case
four
case
balanc
transloc
sole
abnorm
microarray
analysi
show
normal
result
expect
case
microarray
analysi
reveal
addit
chromosom
aberr
includ
heterozyg
homozyg
larg
genom
submicroscop
imbal
delet
breakpoint
recurr
transloc
lowlevel
mosaic
aneusomi
loh
howev
four
case
also
abnorm
detect
gbandingfish
detect
microarray
analysi
clinic
signific
find
detect
microarray
analysi
includ
delet
gene
two
aml
patient
myc
amplif
one
case
aml
cll
homozyg
delet
two
case
ball
delet
two
ball
patient
delet
one
case
aml
ball
addit
nine
region
loh
detect
involv
clinic
signific
gene
result
demonstr
ad
benefit
incorpor
microarray
clinic
practic
enhanc
detect
clinic
signific
alter
hematolog
malign
develop
valid
clinic
sequenc
assay
use
rnaseq
direct
treatment
relaps
pediatr
cancer
marisa
colbi
mani
larri
robin
ira
sponsor
david
brun
depart
molecular
genet
school
medicin
univers
virginia
charlottesvil
va
background
cancer
continu
lead
caus
death
children
unit
state
aim
studi
develop
clinic
valid
rnasequenc
rnaseq
assay
formalinfix
paraffinembed
ffpe
tumor
tissu
detect
action
mutat
pediatr
cancer
relaps
patient
less
chanc
eventfre
surviv
method
studi
ffpe
tissu
tumor
previous
identifi
gene
amplif
andor
overexpress
clinic
valid
method
purifi
rna
quantifi
evalu
use
nanodrop
rna
invitrogen
quantit
qubit
rna
broadrang
assay
kit
agil
bioanalyz
rna
pico
kit
amr
rna
integr
number
rang
valu
major
sampl
purifi
sampl
sonic
ensur
suffici
fragment
rna
sampl
sequenc
illumina
miseq
platform
manual
analysi
overexpress
perform
first
four
sampl
withinsampl
normal
gene
interest
accomplish
select
nine
housekeep
gene
express
sampl
match
normal
tissu
unavail
data
cancer
genom
atla
tcga
databas
use
comparison
result
bioinformat
pipelin
develop
defin
approxim
suitabl
housekeep
gene
normal
result
abstract
submiss
four
specimen
analyz
contain
duplic
myc
egfr
mutat
four
sampl
multiplex
sequenc
one
miseq
flow
cell
lane
overexpress
egfr
detect
manual
analysi
coverag
insuffici
produc
read
exon
egfr
gene
order
detect
mutat
therefor
one
specimen
per
flow
cell
sequenc
subsequ
run
time
abstract
submiss
tcga
databas
normal
control
data
tissu
type
myc
sampl
analysi
myc
data
analyz
bioinformat
pipelin
conclus
describ
proofofprincipl
clinic
valid
wholetranscriptom
rnaseq
assay
order
detect
overexpress
clinic
relev
gene
cancer
patient
lisfacilit
activ
surveil
detect
immun
refractori
patient
earlier
passiv
surveil
erik
g
jenson
ann
burbank
nanci
dunbar
depart
patholog
dartmouthhitchcock
medic
center
lebanon
nh
background
platelet
transfus
plttxn
recipi
repeatedli
fail
achiev
adequ
correct
count
increment
cci
investig
hla
antibodi
respons
transfus
may
improv
provid
hla
crossmatchcompat
plttxn
institut
identif
patient
achiev
passiv
surveil
ps
reli
physician
recognit
prompt
investig
hla
antibodi
test
hlaabt
theoret
laboratori
inform
system
li
configur
achiev
activ
surveil
automat
calcul
cci
follow
everi
plttxn
flag
patient
may
benefit
hlaabt
object
determin
whether
invest
enabl
warrant
method
retrospect
studi
compar
histor
perform
ps
hypothet
identifi
patient
hla
antibodi
popul
consist
patient
posit
hlaabt
subsequ
support
crossmatch
hla
compat
plttxn
simul
cci
calcul
plttxn
preced
hlaabt
inadequ
respons
defin
cci
calcul
postplttxn
laboratori
drawn
within
hour
platelet
dispens
earliest
activ
surveil
detect
date
easdd
defin
date
two
consecut
inadequ
respons
observ
easdd
compar
patient
plttxn
histori
determin
mani
addit
plttxn
beyond
easdd
patient
receiv
prior
hlaabt
investig
possibl
may
result
increas
hlaabt
also
appli
algorithm
retrospect
everi
inpati
hematologyoncolog
ward
receiv
plttxn
octob
result
eight
immunerefractori
patient
diagnos
via
ps
patient
would
investig
potenti
hlaabt
earlier
use
algorithm
patient
receiv
averag
five
plttxn
rang
median
easdd
posit
hlaabt
applic
algorithm
inpati
identifi
two
addit
patient
investig
studi
period
patient
neg
hla
antibodi
follow
hlaabt
conclus
identifi
immun
refractori
patient
earlier
ps
potenti
spare
patient
addit
incompat
platelet
transfus
earlier
provis
compat
unit
activ
surveil
may
howev
result
increas
hla
antibodi
test
patient
nonimmun
explan
platelet
refractori
use
singlenucleotid
variant
ancestri
determin
cancer
predisposit
nextgener
sequenc
assay
patrick
c
mathia
noah
g
hoffman
colin
c
pritchard
brian
h
shirt
depart
laboratori
medicin
univers
washington
seattl
wa
review
genet
laboratori
data
determin
patient
ancestri
help
provid
appropri
interpret
variant
observ
select
popul
well
provid
addit
qualiti
control
metric
identifi
possibl
sampl
swap
address
need
demonstr
use
open
sourc
softwar
predict
geograph
region
ancestri
patient
sampl
germlin
nextgener
sequenc
assay
sequenc
exon
intron
sequenc
gene
associ
hereditari
cancer
predisposit
appli
softwar
program
call
locat
ancestri
seequenc
read
laser
use
princip
compon
analysi
pca
captur
variat
sampl
singlenucleotid
variant
rel
refer
data
human
genom
divers
project
method
suit
target
sequenc
assay
restrict
coverag
refer
correspond
target
region
genom
result
analysi
use
build
twodimension
ancestri
map
refer
pca
space
repres
data
refer
individu
cover
eight
broad
geograph
region
includ
group
mix
race
addit
appli
knearest
neighbor
knn
algorithm
princip
compon
classifi
sampl
provid
discret
result
ancestri
predict
use
approach
analyz
patient
sampl
follow
selfreport
ancestri
distribut
nonashkenazi
european
ashkenazi
latin
american
asian
african
nativ
american
middl
eastern
mix
ancestri
ancestri
predict
knn
concord
selfreport
nonashkenazi
european
asian
middl
eastern
sampl
without
mix
background
fifteen
ashkenazi
sampl
classifi
european
two
classifi
middl
eastern
refer
data
set
includ
individu
mix
race
individu
mix
background
predict
knn
one
parent
ancestri
ancestri
group
lie
parent
group
pca
space
sampl
sampl
posit
graph
first
two
princip
compon
rel
refer
individu
consist
patient
selfreport
ancestri
work
demonstr
addit
inform
nextgener
sequenc
data
may
appli
qualiti
control
addit
person
interpret
variant
detect
techniqu
batch
sampl
extract
improv
precis
turnaround
time
measur
tacrolimu
immunoassay
michael
alberti
alan
fukuchi
anthoni
w
butch
kathleen
kelli
depart
patholog
laboratori
medicin
univers
california
lo
angel
lo
angel
ca
current
method
measur
immunosuppress
includ
manual
offlin
extract
individu
sampl
autom
onlin
extract
method
method
pose
challeng
offlin
extract
hundr
individu
sampl
per
day
result
hand
fatigu
increas
turnaround
time
tat
wherea
onlin
extract
method
compromis
sensit
precis
regard
develop
batch
offlin
extract
method
use
conjunct
abbott
architect
platform
measur
tacrolimu
concentr
whole
blood
compar
analyt
perform
method
offlin
extract
individu
sampl
pretreat
protein
precipit
drug
extract
individu
edta
wholeblood
specimen
requir
prior
use
architect
tacrolimu
immunoassay
modifi
pretreat
step
centrifug
rack
system
could
accommod
sampl
one
time
total
assay
imprecis
cv
determin
patient
sampl
pool
duplic
day
mean
tacrolimu
concentr
ngml
mean
ngml
individu
offlin
extract
respect
batch
extract
function
sensit
cv
determin
duplic
patient
sampl
pool
tacrolimu
concentr
rang
ngml
similar
two
method
ngml
method
comparison
studi
use
sampl
renal
transplant
patient
treat
tacrolimu
n
demonstr
two
method
highli
correl
rang
concentr
batch
individu
r
averag
bia
time
analysi
ngml
offlin
individu
vs
batch
extract
sampl
result
time
save
approxim
overal
well
reduct
tat
summari
batch
extract
sampl
tacrolimu
measur
immunoassay
architect
platform
similar
function
sensit
correl
bia
compar
individu
offlin
extract
sampl
addit
batch
extract
demonstr
increas
precis
low
tacrolimu
concentr
result
less
hand
fatigu
small
time
save
compar
individu
offlin
extract
sampl
thu
improv
patient
care
paraneoplast
antibodi
panel
order
pattern
clinic
manag
util
review
academ
medic
center
chad
teerin
tina
philip
j
sponsor
mari
p
berg
depart
univers
colorado
school
medicin
aurora
co
sens
larg
proport
paraneoplast
antibodi
panel
pap
test
result
neg
costcontrol
initi
place
undertook
util
review
assess
order
pattern
clinic
manag
posit
result
queri
laboratori
result
databas
identifi
pap
test
order
period
systemat
review
clinic
histori
indic
test
order
servic
clinician
respons
result
clinic
outcom
display
result
electron
medic
record
emr
pubm
search
report
pap
util
review
best
practic
undertaken
least
one
antibodi
identifi
test
repres
patient
serum
evalu
much
less
like
posit
order
directli
indirectli
neurologist
cerebrospin
fluid
test
rare
posit
case
posit
result
either
interpret
neg
acknowledg
posit
order
physician
emr
posit
result
led
chang
manag
commonli
immunotherapi
andor
search
occult
malign
strong
associ
histori
autoimmun
diseas
posit
result
posit
test
three
patient
posit
test
remot
histori
malign
two
breast
one
bladder
known
one
patient
concurr
malign
thyroid
two
diagnos
small
cell
lung
carcinoma
anaplast
astrocytoma
month
follow
posit
result
despit
origin
neg
malign
screen
review
report
emr
reveal
posit
result
report
see
report
rather
posit
synopt
result
review
section
discern
result
difficult
due
report
complex
lack
segreg
posit
result
top
report
peerreview
report
directli
address
pap
util
best
practic
identifi
test
result
posit
result
pap
much
less
like
posit
order
nonneurologist
suggest
role
gatekeep
longterm
surveil
patient
posit
pap
result
may
necessari
identifi
occult
malign
misinterpret
lack
acknowledg
posit
test
worrisom
investig
ongo
discern
root
caus
report
emr
synopt
result
review
section
chang
read
posit
rather
see
report
report
list
posit
result
top
postintervent
analysi
ongo
electron
health
record
alert
provid
identifi
excess
order
cardiac
troponin
test
sara
zeke
j
yader
stephen
w
rebecca
fred
depart
medicin
patholog
hennepin
counti
medic
center
minneapoli
mn
new
hospitalwid
cardiac
troponin
ctni
order
set
implement
clinic
practic
base
serial
ctni
test
h
diagnosi
myocardi
infarct
mi
month
fall
order
set
place
initi
one
would
trigger
electron
health
record
ehr
alert
provid
limit
number
order
set
use
rule
inout
mi
purpos
studi
investig
ctni
order
util
new
system
ehr
alert
initi
patient
inclus
subsequ
ehr
review
ctni
tabul
data
includ
demograph
durat
stay
locat
diagnos
ctni
order
result
normal
increas
ctni
result
base
percentil
abbott
architect
evalu
rel
alert
fire
number
ctni
result
prior
subsequ
alert
total
alert
gener
ehr
clinician
request
addit
ctni
order
beyond
initi
serial
order
set
alert
associ
encount
patient
ctni
result
ninetythre
percent
encount
trigger
alert
determin
nonac
relat
per
code
averag
alert
per
encount
rang
encount
per
patient
rang
averag
ctni
result
avail
prior
alert
ctni
result
follow
alert
theori
addit
order
set
complet
approxim
addit
ctni
test
would
report
alert
fire
singl
ctni
result
avail
encount
encount
averag
ctni
result
complet
rang
per
patient
first
ctni
valu
increas
encount
increas
time
encount
initi
increas
ctni
valu
remain
increas
durat
measur
ctni
result
chronic
increas
result
encount
addit
ctni
result
report
first
alert
encount
one
two
three
four
addit
result
alert
initi
trigger
conclud
provid
order
ctni
excess
rule
inout
mi
b
excess
order
predominantli
nonac
patient
c
provid
follow
recommend
mi
guidelin
ctni
order
improv
educ
qualiti
monitor
could
provid
avenu
appropri
util
ctn
test
substanti
financi
save
physician
challeng
potenti
solut
clinic
laboratori
test
order
result
interpret
juli
pamela
john
sponsor
brian
laboratori
program
standard
servic
cdc
atlanta
ga
famili
medicin
univers
illinoi
chicago
chicago
il
school
medicin
new
ct
object
center
diseas
control
prevent
cdc
sought
identifi
challeng
primari
care
physician
face
diagnost
laboratori
test
order
result
interpret
solut
use
current
avail
method
gener
intern
medicin
famili
medicin
physician
survey
uncertainti
order
interpret
laboratori
test
tactic
use
overcom
uncertainti
challeng
test
order
interpret
test
result
perceiv
solut
challeng
help
consult
clinic
laboratori
omb
result
total
physician
respond
survey
physician
report
order
diagnost
laboratori
test
averag
patient
encount
per
week
report
uncertainti
order
test
uncertainti
interpret
result
diagnost
encount
help
tactic
physician
use
overcom
uncertainti
review
erefer
referr
specialist
curbsid
consult
physician
uncertain
test
interpret
frequent
contact
patient
followup
visit
review
medic
histori
common
problemat
challeng
test
order
report
cost
patient
restrict
insur
coverag
challeng
includ
differ
name
test
differ
test
includ
panel
name
test
avail
within
panel
common
problemat
challeng
interpret
use
test
result
problem
receiv
test
result
confus
report
format
physician
endors
varieti
inform
technolog
solut
challeng
solut
wide
avail
conclus
million
patient
visit
primari
care
physician
per
year
level
uncertainti
report
studi
million
visit
test
order
could
affect
order
test
million
patient
interpret
test
result
million
patient
per
year
improv
inform
technolog
clinic
decis
support
system
clear
report
format
access
laboratori
consult
may
reduc
uncertainti
improv
laboratori
test
util
comparison
multipl
respiratori
viral
infect
adult
children
diana
k
sung
fann
wu
sponsor
richard
franci
depart
patholog
cell
biolog
columbia
univers
new
york
ny
benefit
multiplex
pcr
test
respiratori
sampl
detect
coinfect
two
virus
clinic
signific
multipl
respiratori
viral
infect
howev
well
known
object
studi
investig
incid
clinic
signific
tripleposit
tp
respiratori
viral
infect
compar
adult
children
data
respiratori
sampl
test
multiplex
pcr
biofir
diagnost
salt
lake
citi
ut
tertiari
care
hospit
novemb
octob
analyz
coinfect
total
patient
includ
pediatr
adult
test
posit
least
one
viru
thirteen
pediatr
six
adult
patient
test
posit
coinfect
three
virus
tp
pediatr
patient
n
age
year
vs
n
pediatr
patient
test
posit
least
one
viru
tp
adult
patient
age
rang
year
frequent
viru
detect
tp
pediatr
patient
human
rhinovirusenteroviru
n
follow
respiratori
syncyti
viru
n
adenoviru
n
contrast
coronaviru
frequent
detect
adult
tp
patient
n
follow
influenza
n
human
rhinovirusenteroviru
n
ten
tp
pediatr
patient
present
emerg
depart
ed
two
outpati
clinic
one
inpati
major
present
ed
hospit
howev
hospit
discharg
day
expect
manag
none
tp
pediatr
patient
known
medic
condit
caus
immunosuppress
wherea
major
tp
adult
patient
immunocompromis
three
lung
transplant
recipi
two
stage
iii
chronic
lymphocyt
leukemia
four
six
tp
adult
patient
test
inpati
two
outpati
major
sever
clinic
cours
pediatr
group
includ
septic
shock
respiratori
failur
result
indic
tp
respiratori
viral
infect
result
hospit
previous
healthi
infant
toddler
tripl
infect
adult
howev
like
associ
immunocompromis
state
well
complic
prolong
hospit
stay
studi
warrant
investig
impact
multipl
respiratori
viral
infect
realtim
surveil
epidemiolog
trend
drug
abus
overdos
use
mass
urin
toxicolog
joshua
hayden
geoffrey
baird
univers
washington
seattl
wa
drug
overdos
emerg
room
er
visit
repres
substanti
problem
prescript
drug
account
greater
proport
illicit
goal
work
determin
mass
urin
toxicolog
ut
could
provid
realtim
surveil
drug
abus
util
two
separ
ut
assay
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
ga
chromatographi
mass
spectrometri
gcm
assay
lcmsm
assay
util
part
institut
chronic
pain
screen
gcm
assay
use
comprehens
ut
er
data
drugrel
death
obtain
counti
medic
examin
found
preval
prescrib
opioid
chronic
pain
patient
correl
preval
abus
drug
patient
popul
prescript
opioid
five
time
commonli
abus
illicit
cocain
heroin
methamphetamin
oxycodon
methadon
hydrocodon
main
drug
prescrib
abus
also
main
opioid
detect
overdos
patient
er
preval
drug
detect
overdos
patient
mirror
preval
drug
caus
overdos
death
eight
top
common
drug
occur
group
drug
includ
citalopram
diphenhydramin
detect
use
mass
ut
addit
mass
spectrometri
allow
us
detect
obtain
preval
estim
levamisol
clinic
relev
cocain
adulter
estim
preval
confid
interv
statist
indistinguish
estim
drug
enforc
agenc
demograph
age
sex
preval
alcohol
overdos
patient
er
statist
indistinguish
patient
die
overdos
alcohol
preval
work
indic
mass
ut
provid
realtim
surveil
drug
abus
allow
identif
atrisk
patient
demograph
pattern
drug
abus
includ
drug
detect
standard
immunoassay
gener
method
valid
assay
variabl
bodi
fluid
matthew
schrage
geoffrey
baird
andrew
hoofnagl
petri
rainey
depart
laboratori
medicin
univers
washington
seattl
wa
valid
clinic
assay
bodi
fluid
problemat
multipl
way
assay
manufactur
frequent
includ
test
bodi
fluid
among
claim
requir
individu
laboratori
valid
bodi
fluid
test
laboratorydevelop
test
develop
generaliz
method
valid
multipl
analyt
demonstr
matrix
commut
model
effus
vari
composit
made
model
transud
ultrafiltr
patient
serum
pool
use
millipor
amicon
ultra
centrifug
filtrat
system
ultrafiltr
mix
back
pool
serum
vari
proport
creat
rang
matric
specif
mixtur
transudateserum
spike
recoveri
assay
perform
triplic
across
matric
determin
commut
possibl
spike
solut
span
analyt
measur
rang
use
determin
linear
verifi
approach
part
introduc
new
chemistri
analyz
beckman
au
matrix
effect
assess
use
slope
analyt
recoveri
vs
matrix
composit
expect
zero
matrix
effect
slope
statist
differ
zero
bicarbon
creatinin
total
bilirubin
total
protein
albumin
lactat
dehydrogenas
amylas
lipas
triglycerid
confid
interv
slope
clinic
signific
sodium
potassium
chlorid
magnesium
phosphat
serum
urea
nitrogen
glucos
matrix
commut
could
demonstr
cholesterol
assay
confid
interv
slope
novel
approach
serv
excel
model
valid
varieti
assay
matrix
commut
microbiolog
diagnost
manag
team
novel
initi
promot
interpret
individu
laboratori
medicin
jonathan
e
schmitz
charl
w
stratton
carol
rauch
jame
chappel
depart
patholog
microbiolog
immunolog
vanderbilt
univers
medic
center
nashvil
tn
novel
initi
practic
clinic
microbiolog
diagnost
manag
team
microbiolog
initi
evolv
past
year
depart
patholog
microbiolog
immunolog
vanderbilt
univers
medic
center
microbiolog
dmt
involv
daili
coordin
effort
microbiolog
faculti
fellow
patholog
resid
strive
realiz
follow
goal
creat
formal
venu
expert
interpret
challeng
laboratori
find
proactiv
identifi
case
benefit
intervent
monitor
sentinel
result
optim
laboratori
respons
intra
extradepartment
consult
request
scope
microbiolog
dmt
encompass
bacteriolog
virolog
mycolog
molecular
diagnost
along
certain
aspect
parasitolog
infecti
diseas
serolog
microbiolog
refer
test
member
microbiolog
dmt
meet
daili
mf
review
emerg
case
monitor
develop
ongo
case
formul
action
patientbypati
basi
regular
intervent
includ
submit
interpret
commentari
electron
medic
record
advis
manag
clinician
appropri
followon
test
facilit
involv
indic
specialti
servic
particular
infecti
diseas
clinic
pharmaci
infect
control
prevent
present
outlin
gener
workflow
microbiolog
dmt
describ
ad
valu
dmtcenter
microbiolog
servic
patient
care
also
discuss
collater
impact
dmt
aspect
clinic
microbiolog
laboratori
administrativemanag
issu
hous
staff
educ
antimicrobi
stewardship
resourc
util
clinic
laboratori
increas
pressur
make
direct
defin
contribut
posit
patient
outcom
believ
microbiolog
dmt
effect
mechan
clinic
microbiologist
maxim
impact
health
care
practition
system
lupu
erythematosu
complic
macrophag
activ
syndrom
portal
vein
thrombosi
ischem
coliti
autopsi
case
report
yihong
vishnu
reddi
stephani
reilli
depart
patholog
univers
alabama
birmingham
birmingham
al
macrophageactiv
syndrom
ma
sever
potenti
lifethreaten
condit
describ
associ
system
lupu
erythematosu
sle
kawasaki
diseas
system
juvenil
idiopath
arthriti
sjia
hallmark
clinic
laboratori
featur
includ
high
fever
hepatosplenomegali
lymphadenopathi
pancytopenia
liver
dysfunct
dissemin
intravascular
coagul
dic
hypofibrinogenemia
hyperferritinemia
hypertriglyceridemia
report
white
woman
sle
syndrom
admit
sepsi
acut
coliti
initi
stabl
condit
declin
despit
therapi
rais
concern
ma
ferritin
level
significantli
increas
ngml
along
posit
dic
laboratori
result
ddimer
ngml
fibrinogen
mgdl
platelet
inr
high
white
cell
count
die
hospit
day
postmortem
examin
confirm
acut
coliti
involv
segment
reveal
acut
portal
vein
thrombosi
pvt
extens
associ
hepat
necrosi
bone
marrow
hypercellular
hemophagocyt
activ
stain
demonstr
increas
number
macrophag
hemophagocytosi
immedi
caus
death
attribut
ma
associ
pvt
acut
coliti
underli
caus
death
sle
associ
report
sle
ma
sle
thrombosi
incid
ma
sjia
contrast
ma
associ
sle
rare
incid
cytotox
dysfunct
sle
may
lead
persist
excess
expans
activ
cell
macrophag
arteri
andor
venou
thrombosi
wellknown
clinic
entiti
sle
preval
thrombosi
attribut
number
thrombophil
defect
includ
lupu
anticoagul
anticardiolipin
antibodi
pvt
sle
patient
abdomin
surgeri
report
statist
data
found
sle
case
knowledg
first
fatal
case
ma
pvt
sle
patient
highlight
import
consid
rare
complic
need
earli
recognit
immedi
therapeut
intervent
retrospect
evalu
multireview
signout
nextgener
sequenc
assay
target
somat
mutat
cancer
eric
q
konnick
david
wu
brian
h
shirt
jonathan
f
tait
colin
c
pritchard
depart
laboratori
medicin
univers
washington
seattl
wa
introduct
interpret
nextgener
sequenc
ng
assay
perform
clinic
tumor
tissu
challeng
due
complic
natur
neoplast
tissu
bioinformat
pipelin
necessari
analyz
annot
raw
sequenc
data
broad
inclus
numer
gene
test
panel
necessit
extens
review
understand
relev
pathway
signal
cascad
somat
mutat
analysi
neoplasia
complic
high
mutat
rate
tumor
heterogen
admixtur
normal
tissu
requir
analyst
cautiou
interpret
variant
goal
project
evalu
absolut
compar
perform
resid
medic
director
analysi
multigen
tumor
panel
output
method
evalu
perform
multireview
model
identif
report
signific
find
ng
panel
cancer
neoplasm
sequenti
patient
use
target
captur
combin
ng
illumina
hiseq
miseq
instrument
allow
us
detect
mutat
copi
number
chang
structur
variant
relev
cancer
treatment
prognosi
diagnosi
result
independ
analyz
two
four
review
includ
least
one
senior
patholog
resid
one
physicianlevel
laboratori
medicin
faculti
result
deem
signific
review
compil
discuss
consensu
signout
session
compar
variant
identifi
resid
medic
director
assess
rate
agreement
review
inclus
final
patient
report
result
patient
bioinformat
pipelin
identifi
variant
reduc
remov
intron
noncod
synonym
substitut
remain
variant
brought
consensu
confer
possibl
inclus
final
patient
report
number
variant
per
sampl
rang
total
variant
report
across
case
variant
report
five
patient
report
variant
identifi
one
review
major
variant
identifi
resid
review
result
discuss
consensu
confer
report
select
singl
review
case
conclus
use
multipl
independ
review
includ
resid
evalu
somat
mutat
neoplast
tissu
identifi
multigen
ng
panel
increas
yield
report
result
may
limit
report
incident
find
discuss
standard
approach
report
novel
method
monitor
therapi
guid
treatment
decis
new
era
anticoagul
jaim
noguez
jame
ritchi
depart
patholog
laboratori
medicin
emori
univers
school
medicin
atlanta
ga
number
oral
administ
drug
recent
introduc
market
select
inhibit
singl
enzym
coagul
cascad
new
oral
anticoagul
hold
promis
overcom
limit
associ
tradit
use
anticoagul
predict
therapeut
advantag
perhap
one
appeal
attribut
new
drug
requir
routin
monitor
due
predict
pharmacolog
profil
fix
weightbas
dose
regimen
specif
clinic
situat
howev
detect
quantifi
may
requir
clinic
decis
make
periop
patient
manag
monitor
highrisk
patient
rule
inout
advers
drug
event
bleed
event
manag
mani
challeng
exist
monitor
new
drug
current
coagul
assay
demonstr
limit
clinic
use
inabl
accur
reliabl
measur
concentr
need
aris
made
clinician
wari
prescrib
use
water
acquiti
uplc
coupl
water
xevo
tq
ms
develop
valid
sensit
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
method
simultan
quantifi
four
oral
anticoagul
drug
warfarin
dabigatran
rivaroxaban
apixaban
market
plasma
sampl
quantif
base
multiplereact
monitor
use
stabl
isotopelabel
drug
analog
intern
standard
method
allow
reproduc
accur
quantif
warfarin
dabigatran
rivaroxaban
apixaban
use
plasma
limit
quantif
ngml
respect
linear
establish
ngml
signific
interfer
observ
lipem
hemolyz
icter
plasma
sampl
signific
matrix
effect
observ
sampl
collect
green
heparin
light
blue
citrat
lavend
edta
yellow
acd
top
bd
vacutain
tube
multicompon
ms
method
determin
anticoagul
first
kind
provid
laboratori
novel
costeffect
way
monitor
therapi
guid
treatment
decis
new
era
oral
anticoagul
drug
comparison
two
human
gonadotropin
immunoassay
use
earli
pregnanc
embryo
implant
evalu
jing
cao
samantha
miller
michael
tsai
depart
laboratori
medicin
patholog
univers
minnesota
minneapoli
mn
human
chorion
gonadotropin
subunit
core
fragment
major
form
hcg
found
urin
sampl
pregnanc
nevertheless
multipl
form
hcg
variant
present
urin
earli
pregnanc
object
studi
compar
perform
two
immunoassay
use
earli
pregnanc
embryo
implant
evalu
effect
aspirin
gestat
reproduct
eager
studi
conduct
nation
institut
child
health
human
develop
standard
nick
intact
hcg
nick
hcg
hcgn
obtain
nation
institut
biolog
standard
control
nibsc
measur
use
immunoassay
kit
diagnost
autom
calabasa
ca
biovendor
candler
nc
use
assay
urin
sampl
eager
studi
earli
pregnanc
week
implant
evalu
perform
univers
minnesota
advanc
research
diagnost
laboratori
nibsc
standard
serial
dilut
assay
diluent
miuml
assay
reactiv
standard
hcg
variant
calcul
percentag
measur
concentr
concentr
calcul
dilut
concentr
miuml
reactiv
assay
diagnost
autom
biovendor
respect
miuml
reactiv
two
assay
test
nibsc
standard
hcg
variant
reactiv
overal
higher
assay
diagnost
autom
biovendor
conclud
two
immunoassay
use
earli
pregnanc
embryo
implant
evalu
eager
studi
assay
diagnost
autom
show
higher
reactiv
hcg
variant
biovendor
concentr
miuml
indic
need
establish
assayspecif
hcg
refer
rang
earli
pregnanc
studi
test
lupu
anticoagul
two
differ
methodolog
provid
addit
diagnost
inform
tertiari
care
hospit
daimon
p
adrianna
z
elisabeth
peter
h
susan
j
david
patholog
medicin
divis
hematolog
rheumatologyimmunolog
brigham
women
hospit
boston
antiphospholipid
antibodi
syndrom
character
laboratori
evid
antiphospholipid
antibodi
eg
lupu
anticoagul
la
anticardiolipin
andor
clinic
set
venou
arteri
thrombosi
specif
pregnanc
morbid
recent
intern
societi
thrombosi
haemostasi
recommend
laboratori
util
two
differ
test
modal
detect
la
hospit
tertiari
care
center
test
patient
presenc
la
set
thrombosi
pregnanc
morbid
evalu
connect
tissu
diseas
mani
asymptomat
patient
prolong
ptt
also
test
la
accord
new
recommend
coagul
laboratori
institut
dilut
russel
viper
venom
time
drvvt
addit
previous
use
pttbase
method
detect
la
test
result
track
period
posit
result
total
case
detect
ptt
method
alon
drvvt
method
modal
confirm
case
la
antiphospholipid
antibodi
syndrom
detect
singl
la
test
modal
la
result
correl
anticardiolipin
level
patient
test
modal
case
respect
la
detect
simultan
test
modal
like
coincid
high
titer
anticardiolipin
antibodi
chart
review
perform
correl
clinic
histori
laboratori
find
la
asymptomat
patient
prolong
ptt
persist
diagnost
challeng
patient
like
posit
la
detect
pttbase
method
patient
posit
la
detect
drvvt
like
histori
thrombosi
patient
neg
la
detect
ptt
howev
exclud
asymptomat
patient
analysi
reveal
equival
increas
thrombot
risk
patient
posit
la
detect
either
ptt
drvvtbase
method
find
show
addit
second
test
modal
la
provid
addit
diagnost
inform
may
help
identifi
patient
futur
risk
thrombosi
computeraid
diagnosi
classic
hodgkin
lymphoma
chl
flow
cytometri
david
p
ng
david
wu
jonathan
fromm
depart
laboratori
medicin
divis
hematopatholog
univers
washington
seattl
wa
object
previous
describ
manual
method
diagnos
chl
flow
cytometri
depend
sequenti
gate
small
popul
hodgkinre
sternberg
hr
cell
wide
standard
sought
evalu
machin
learn
method
classifi
case
without
chl
well
determin
novel
featur
may
use
classifi
case
method
flow
cytometri
data
clinic
case
use
previous
describ
ninecolor
panel
flow
cytometri
analyz
use
algorithm
develop
python
scikitlearn
modul
seventyeight
twodimension
histogram
gener
use
flow
cytometri
data
reciproc
power
function
appli
favor
rare
event
featur
vector
dimension
reduc
princip
compon
analysi
pca
ensembl
method
rescal
support
vector
machin
svm
gradient
boost
random
forest
classifi
appli
result
three
classifi
show
statist
differ
perform
accuraci
stratifi
kfold
crossvalid
interestingli
nearli
set
case
misclassifi
three
method
whole
falseposit
case
falseneg
case
dimension
reduct
ensembl
method
select
point
region
dimension
reduct
pca
demonstr
better
perform
lower
overhead
given
larg
train
set
addit
inclus
exclus
hr
gate
cell
littl
impact
overal
perform
select
support
vector
svm
dimension
reduct
ensembl
method
conclus
show
computeraid
classif
chl
flow
case
possibl
use
adjunct
manual
diagnosi
case
three
classifi
provid
probabilist
confid
result
cutoff
chosen
minim
fals
neg
better
serv
screen
tool
interestingli
appear
featur
beyond
recognit
discret
hr
popul
use
classif
case
hypothes
may
immunophenotyp
abnorm
tcell
infiltr
addit
research
requir
determin
characterist
immunophenotyp
infiltr
parathyroid
hormon
pth
measur
fineneedl
aspir
biopsi
fnab
wash
identifi
parathyroid
tissu
high
specif
hemamalini
ketha
michael
lasho
alicia
algecirasschimnich
depart
laboratori
medicin
patholog
mayo
clinic
rochest
mn
background
measur
pth
fineneedl
aspir
biopsi
fnab
wash
follow
ultrasoundguid
biopsi
gain
popular
mean
provid
local
suspect
parathyroid
lesion
differenti
parathyroid
tissu
thyroid
nodul
interpret
pth
concentr
washout
influenc
collect
volum
collect
techniqu
pth
assay
use
object
establish
diagnost
cutoff
pth
fnab
needl
wash
identifi
parathyroidderiv
tissu
specif
method
retrospect
studi
mayo
clinic
patient
pth
measur
fnab
needl
wash
june
septemb
identifi
fnab
wash
perform
rins
biopsi
needl
expuls
cellular
materi
cytolog
ml
normal
salin
needl
wash
five
pass
per
biopsi
site
pool
final
volum
ml
sent
refriger
laboratori
test
pth
measur
use
roch
elecsi
assay
indianapoli
medic
record
review
document
clinic
present
pth
concentr
serum
fnab
wash
imag
procedur
cytolog
patholog
outcom
statist
analysi
perform
use
jmp
softwar
version
sa
result
ninetythre
fnab
wash
specimen
patient
femal
male
age
mean
sd
year
test
patient
suffici
clinic
inform
classifi
biopsi
structur
unequivoc
parathyroid
n
nonparathyroid
tissu
n
roc
curv
analysi
produc
area
curv
auc
pth
cutoff
pgml
show
specif
sensit
posit
predict
valu
seven
parathyroid
specimen
miss
fnab
wash
three
also
miss
cytolog
use
fnab
wash
pth
serum
pth
ratio
discrimin
parathyroid
nonparathyroid
tissu
specif
sensit
roc
auc
histologyconfirm
parathyroid
specimen
correctli
identifi
pth
pgml
wherea
detect
cytolog
conclus
fnab
wash
pth
concentr
pgml
pth
fnab
wash
serum
ratio
select
achiev
specif
henc
avoid
unnecessari
surgeri
pth
cutoff
pgml
show
slightli
better
diagnost
sensit
cytolog
still
suboptim
perform
pth
fnab
wash
might
improv
accur
sampl
biopsi
structur
failur
laboratori
supplement
aminotransferas
assay
pyridox
phosphat
lead
discrep
result
case
report
investig
discrep
serum
ast
alt
activ
patient
subgroup
john
r
craig
dina
n
lynn
darci
r
nikola
laboratori
medicin
patholog
mayo
clinic
rochest
mn
permanent
tpmg
northern
california
region
laboratori
berkeley
ca
ifcc
recommend
aspart
aminotransferas
ast
alanin
aminotransferas
alt
assay
includ
cofactor
requir
maxim
activ
despit
recommend
cap
profici
test
survey
show
laboratori
roch
chemistri
analyz
report
use
reagent
present
case
report
patient
defici
macroenzym
ast
present
discrep
ast
result
sever
laboratori
lead
unnecessari
workup
addit
test
object
studi
compar
serum
ast
alt
measur
use
reagent
without
assess
clinic
impact
gener
patient
popul
patient
defici
patient
macroast
residu
sampl
liver
function
test
n
serum
ast
ul
test
n
plasma
mcgl
macroast
case
n
serum
obtain
ast
alt
measur
roch
coba
use
altl
altlp
astl
astlp
reagent
roch
serum
plasma
valid
reagent
linear
regress
analysi
method
comparison
ast
alt
yield
astl
astlp
altl
altlp
ast
eight
patient
would
classifi
differ
accord
manufactur
refer
interv
ri
use
reagent
patient
nine
increas
ast
alt
patient
would
classifi
differ
accord
manufactur
ri
use
reagent
patient
increas
alt
patient
plasma
mcgl
greater
increas
median
rang
p
ast
activ
upon
supplement
compar
normal
plasma
concentr
mcgl
patient
macroast
greater
increas
ast
activ
compar
patient
without
macroast
median
rang
p
conclus
patient
sever
defici
andor
macroast
higher
risk
discord
ast
result
due
inconsist
use
supplement
case
report
data
support
univers
adopt
ast
alt
assay
improv
harmon
reduc
clinic
confus
aris
discrep
liver
enzym
result
laboratori
iron
level
risk
hepatocellular
carcinoma
liver
explant
margaret
e
geoffrey
paul
e
matthew
depart
medicin
univers
washington
seattl
wa
excess
iron
accumul
liver
contribut
liver
fibrosi
cirrhosi
hepatocellular
carcinoma
hcc
anim
model
dietari
iron
overload
shown
caus
develop
preneoplast
nodul
hepatocellular
carcinoma
absenc
fibrosi
cirrhosi
exact
mechan
iron
hepatocarcinogen
unclear
like
due
increas
gener
reactiv
oxygen
speci
studi
aim
determin
whether
variou
indic
iron
statu
could
valu
predict
presenc
hepatocellular
carcinoma
liver
explant
endstag
liver
diseas
perform
multivari
analys
liver
explant
institut
evalu
independ
associ
multipl
indic
iron
statu
presenc
hcc
serum
ferritin
iron
afp
tibc
well
semiquantit
liver
tissu
iron
iron
stain
assess
util
predictor
hcc
statu
gener
roc
curv
hcc
present
liver
explant
etiolog
cirrhosi
primarili
includ
hcvhbv
infect
alcohol
nonalcohol
steatohepat
primari
biliari
cirrhosi
sever
other
also
repres
analys
two
multivari
analys
show
statist
signific
relationship
four
iron
indic
presenc
hcc
p
area
curv
auc
individu
roc
analys
serum
ferritin
serum
iron
tibc
semiquantit
tissu
iron
serum
afp
signific
neg
predict
effect
lower
serum
ferritin
level
ngml
odd
ratio
ci
logist
model
contain
data
point
serum
iron
log
ferritin
tissu
iron
afp
abl
predict
hcc
auc
accuraci
model
serum
iron
p
afp
p
signific
coeffici
multipl
statist
techniqu
shown
clinic
use
predict
effect
multipl
indic
iron
statu
indic
iron
overload
howev
small
statist
signific
relationship
low
iron
storag
level
measur
serum
ferritin
risk
hcc
liver
explant
suggest
lower
iron
level
minor
protect
effect
diluteandshoot
mass
spectrometri
identifi
hemoglobin
variant
jane
david
patholog
univers
california
san
diego
la
jolla
ca
diego
san
diego
ca
cation
exchang
ce
capillari
zone
electrophoresi
cze
oftentim
insuffici
identifi
specif
hemoglobin
variant
addit
inform
obtain
classic
techniqu
use
mass
spectrometri
ms
confirm
ident
hemoglobin
variant
wash
wholeblood
sampl
known
specimen
valid
previous
unabl
identifi
specimen
cehplc
cze
lyse
water
vv
centrifug
specimen
dilut
electrospray
solvent
acetonitril
formic
acid
inject
onto
capillari
column
water
acquiti
uplc
desalt
coupl
qstar
elit
qtof
mass
spectromet
ab
sciex
mass
spectra
deconvolut
analyz
peak
distribut
indic
mass
differ
due
singl
amino
acid
variant
chain
presenc
normal
distribut
peak
spectra
indic
mass
differ
wildtyp
hemoglobin
chain
variant
variabl
mass
spectrometri
amu
therebi
rule
variant
larger
mass
differ
hemoglobin
jbaltimor
asp
dpunjab
gln
hemoglobin
c
ly
indic
cehplc
cze
confirm
ms
experiment
amu
amu
respect
correspond
calcul
hemoglobin
athensgeorgia
ly
gpest
asn
jhabana
glu
calcul
also
confirm
ms
experiment
amu
case
approach
yield
multipl
possibl
variant
posit
amino
acid
substitut
confirm
digest
tandem
ms
protein
sequenc
possibl
sampl
volum
remain
author
grate
acknowledg
dr
majid
ghassemian
elizabeth
komiv
ucsd
biomolecular
proteom
mass
spectrometri
facil
train
usag
instrument
frequenc
overlook
abnorm
result
urin
blood
identifi
retrospect
expand
screen
toxic
element
induct
coupl
plasma
mass
spectrometri
highlight
limit
current
screen
approach
sarah
jake
mongola
christian
frederick
g
patholog
univers
utah
laboratori
salt
lake
ut
institut
clinic
experiment
patholog
salt
lake
citi
ut
time
diagnosi
heavi
metal
poison
repres
signific
issu
clinic
toxicolog
addit
overlap
symptom
exposur
sever
heavi
metal
present
challeng
physician
laboratori
ensur
appropri
test
order
readili
avail
histor
laboratori
provid
quantit
panel
compris
element
commonli
involv
poison
howev
sampl
type
ie
urin
blood
also
challeng
due
complex
biolog
distribut
heavi
metal
contrast
common
mani
hospit
use
pointofcar
toxicolog
screen
immunoassaybas
laboratori
test
comprehens
mass
screen
provid
qualit
compound
class
compound
identif
urin
serumplasma
overdos
situat
metal
drug
exposur
retrospect
review
result
heavi
metal
panel
blood
contain
three
n
four
n
element
reveal
overal
posit
defin
least
one
element
elev
refer
interv
panel
low
posit
rate
rais
possibl
current
design
panel
may
miss
potenti
element
exposur
determin
comprehens
heavi
metal
screen
induct
coupl
spectrometri
would
clinic
util
proactiv
screen
blood
urin
specimen
submit
trace
element
test
origin
order
test
submit
specimen
includ
individu
element
well
panel
contain
three
six
element
blood
urin
submit
urin
specimen
neg
origin
order
element
detect
concentr
greater
establish
refer
interv
aluminum
arsen
bismuth
chromium
cobalt
iodin
manganes
nickel
selenium
zinc
submit
blood
specimen
neg
origin
order
element
detect
concentr
greater
establish
refer
interv
antimoni
arsen
lead
manganes
percent
posit
result
identifi
wider
screen
protocol
known
potenti
toxic
element
taken
togeth
identifi
challeng
accur
detect
element
exposur
suggest
expand
element
screen
panel
may
clinic
util
unknown
element
exposur
case
good
syndrom
full
genom
analysi
patient
famili
jonathan
h
micki
h
mark
adam
farid
f
katherin
mark
sponsor
enriqu
laboratori
medicin
center
medicin
system
research
institut
univers
california
san
francisco
ca
medicin
divis
infecti
diseas
depart
microbiolog
immunolog
univers
michigan
medic
school
ann
arbor
mi
good
syndrom
rare
disord
associ
thymoma
sever
humor
cellular
immunodefici
mark
absenc
b
cell
peripher
blood
common
find
genet
environment
risk
factor
diseas
unknown
although
hypothes
possibl
genet
caus
propos
mutat
taci
ikaro
present
case
man
histori
thymoma
resect
age
year
myasthenia
gravi
recurr
pneumonia
hypogammaglobulinemia
chronic
prednison
therapi
present
diarrhea
secondari
cmv
coliti
dissemin
mycobacterium
avium
complex
infect
new
diagnosi
scleros
cholang
hospit
cours
complic
candida
fungemia
vre
bacteremia
presum
fungal
endophthalm
laboratori
evalu
notabl
absolut
lymphocyt
count
normal
rang
admiss
absolut
bcell
count
normal
rang
absolut
bcell
count
low
least
year
patient
absolut
tcell
count
also
decreas
normal
rang
hiv
test
neg
natur
killer
cell
also
decreas
normal
rang
patient
total
serum
igg
mgdl
normal
rang
mgdl
subclass
decreas
due
histori
thymoma
presenc
cellular
humor
immunodefici
diagnosi
good
syndrom
made
patient
parent
sister
consent
blood
collect
wholegenom
sequenc
analysi
univers
california
san
francisco
irb
besid
patient
famili
member
report
histori
recurr
infect
autoimmun
condit
wholegenom
sequenc
perform
complet
genom
use
highthroughput
dna
nanoarray
platform
analysi
kindr
use
ingenu
variant
analysi
show
like
deleteri
mutat
either
propos
loci
associ
good
syndrom
taci
ikaro
result
suggest
possibl
locu
heterogen
good
syndrom
homozyg
deleteri
mutat
gene
annot
involv
immun
cell
regul
detect
proband
analysi
serum
total
holotranscobalamin
methylmalon
acid
diagnosi
vitamin
defici
jeffrey
w
meeusen
maria
willrich
nikola
baumann
alicia
algecirasschimnich
depart
laboratori
medicin
patholog
mayo
clinic
rochest
mn
background
earli
detect
vitamin
defici
essenti
prevent
potenti
seriou
complic
biochem
evalu
defici
includ
measur
total
methylmalon
acid
mma
use
total
first
line
screen
limit
low
sensit
mma
increas
individu
defici
lack
specif
especi
patient
impair
renal
function
limit
util
recent
assay
holotranscobalamin
holotc
bioavail
complex
becom
commerci
avail
howev
util
holotc
detect
defici
controversi
object
evalu
perform
holotc
mma
identifi
defici
method
studi
cohort
includ
healthi
individu
n
patient
undergo
defici
evalu
n
clinic
defici
n
verifi
chart
review
serum
holotc
assay
use
abbott
architect
total
use
beckman
unicel
dxi
mma
lcmsm
perform
analyt
alon
twotier
approach
total
holotc
follow
mma
evalu
receiv
oper
curv
roc
analysi
result
holotc
central
percentil
normal
cohort
pmoll
clinic
cohort
median
valu
decreas
clinic
defici
holotc
pmoll
iqr
pmoll
vs
pmoll
iqr
pmoll
total
pmoll
iqr
ngl
vs
ngl
iqr
ngl
increas
mma
nmolml
iqr
nmolml
vs
nmolml
iqr
p
case
roc
analysi
identifi
optim
cutoff
holotc
pmoll
auc
sensit
specif
ngl
auc
sensit
specif
mma
nmoll
auc
sensit
specif
diagnost
effici
holotc
total
mma
effici
current
twotier
approach
confirm
total
ngl
mma
cutpoint
nmoll
show
sensit
specif
use
similar
approach
confirm
holotc
pmoll
mma
cutpoint
nmoll
sensit
specif
use
holotc
initi
screen
requir
fewer
mma
confirm
compar
vs
conclus
serum
holotc
effici
biomark
clinic
defici
use
holotc
initi
screen
could
decreas
number
mma
confirmatori
test
lead
decreas
cost
time
result
increas
diagnost
sensit
challeng
clinic
impact
visual
hemolysi
detect
trace
toxic
element
assess
serum
meghan
carri
j
kira
kelli
l
christian
frederick
g
patholog
univers
utah
health
scienc
center
salt
lake
ut
institut
clinic
experiment
patholog
salt
lake
ut
laboratori
salt
lake
citi
ut
current
state
evalu
presenc
hemolysi
serum
sampl
assess
determin
visual
inspect
adequ
identifi
hemolyz
sampl
trace
element
test
addit
effect
vari
degre
hemolysi
serum
sampl
test
select
trace
element
assess
determin
degre
hemolysi
would
affect
report
valu
current
laboratori
protocol
requir
hemolysi
evalu
visual
insid
cleanroom
test
facil
reduc
environment
contamin
sampl
assign
hemolysi
index
hi
mgdl
hemoglobin
sampl
greater
reject
test
assess
adequaci
visual
assign
process
serum
sampl
submit
routin
clinic
test
visual
verifi
spectrophotometr
use
roch
coba
sampl
hi
less
determin
accept
clinic
test
correctli
identifi
compar
valu
provid
measur
hemolysi
sampl
visual
hi
greater
correctli
identifi
hi
greater
sampl
incorrectli
identifi
base
spectrophotometr
measur
determin
clinic
signific
hemolysi
serum
trace
toxic
element
measur
pool
serum
sampl
measur
hemolysi
index
pool
wash
rbc
use
rbc
pool
hemolyz
exposur
three
freezethaw
cycl
serum
rbc
pool
mix
achiev
hemolyz
rbc
serum
mix
sampl
analyz
cu
zn
co
mn
ni
use
induct
coupl
spectrometri
clinic
signific
increas
ni
zn
respect
observ
hi
rbc
contrast
rel
littl
impact
seen
serum
measur
copper
cobalt
manganes
hi
less
summari
visual
inspect
hi
adequ
techniqu
identifi
hemolysi
serum
sampl
howev
improv
need
made
final
determin
incorrectli
identifi
sampl
true
hi
less
reduc
fals
sampl
reject
addit
find
indic
fals
elev
result
due
hemolysi
potenti
neg
impact
patient
care
inaccur
indic
toxic
mask
defici
lead
inappropri
medic
treatment
simultan
identif
oral
antidiabet
drug
plasma
urin
liquid
mass
spectrometri
brenda
b
geoffrey
kamisha
l
patholog
univers
utah
salt
lake
citi
ut
laboratori
salt
lake
citi
ut
oral
antidiabet
drug
oad
util
manag
hyperglycemia
type
ii
diabet
despit
efficaci
treatment
inadvert
intent
overdos
oad
caus
lifethreaten
hypoglycemia
detect
oad
use
investig
hypoglycemia
unknown
origin
may
differenti
hypoglycemia
caus
oad
oppos
insulinoma
liquid
mass
spectrometri
lcmsm
method
develop
detect
oad
plasma
urin
addit
retrospect
analysi
test
result
evalu
determin
posit
rate
oad
liquidliquid
extract
plasma
urin
sampl
follow
separ
detect
nine
oad
first
gener
chlorpropamid
acetohexamid
tolbutamid
tolazamid
second
gener
glipizid
glyburid
glimepirid
repaglinid
nateglinid
lcmsm
use
atmospher
pressur
chemic
ioniz
identif
specif
drug
achiev
two
ion
transit
select
reaction
monitor
mode
method
comparison
extern
laboratori
show
concord
analyt
plasma
except
glyburid
analyt
recoveri
rang
plasma
urin
limit
quantit
ngml
firstgener
oad
ngml
secondgener
oad
within
betweenrun
imprecis
rang
plasma
urin
respect
imprecis
chlorpropamid
acetohexamid
tolbutamid
variabl
due
lack
isotop
label
intern
standard
analyt
commonli
use
medic
eg
acetaminophen
interfer
assay
howev
glipizid
result
neg
affect
hemolysi
lipemia
effect
collect
tube
type
evalu
sodium
heparin
edta
serum
kfna
oxal
tube
tube
type
neg
bia
chlorpropamid
tolazamid
neg
bia
serum
edta
tube
use
retrospect
analysi
patient
result
plasma
show
posit
rate
glipizid
glyburid
glimepirid
commonli
identifi
urin
glipizid
detect
patient
assay
sensit
specif
qualit
detect
nine
oad
use
investig
clinic
case
hypoglycemia
unknown
origin
use
plasma
urin
genom
databas
perform
improv
documentbas
databas
architectur
wade
l
schulz
donn
k
felker
brent
g
nelson
sponsor
michael
linden
univers
minnesota
minneapoli
mn
clinic
genom
sequenc
becom
increasingli
common
cost
sequenc
declin
effici
improv
underli
sequenc
technolog
improv
dramat
softwar
solut
data
storag
analysi
kept
pace
studi
consid
whether
new
databas
architectur
documentori
databas
improv
effici
genom
data
storag
analysi
use
cloud
comput
platform
compar
write
speed
queri
perform
common
relat
mysql
documentori
mongodb
databas
tradit
disk
solidst
storag
devic
singlenucleotid
polymorph
data
dbsnp
pars
load
platform
multipl
queri
perform
determin
benefit
platform
found
time
need
load
individu
record
similar
bulk
load
data
mongodb
signific
perform
benefit
addit
queri
perform
documentori
mongodb
approxim
two
order
magnitud
faster
mysql
surprisingli
found
standard
disk
storag
within
cloud
platform
perform
significantli
better
write
oper
compar
solidst
drive
like
due
randomwrit
natur
oper
data
demonstr
documentori
databas
provid
signific
benefit
new
databas
system
within
field
genom
also
underscor
need
perform
test
new
hardwar
chang
vendor
storag
type
may
lead
unintend
consequ
system
perform
given
overal
benefit
cost
genom
data
storag
significantli
reduc
migrat
documentori
databas
architectur
use
intern
control
tcell
nkcell
subset
object
measur
flow
cytometr
qualiti
alicia
hunt
stephen
p
ten
eyck
fiona
e
craig
depart
patholog
univers
pittsburgh
school
medicin
pittsburgh
pa
flow
cytometri
studi
import
part
evalu
potenti
hematopoiet
neoplasm
nkcell
neoplasm
may
subtl
differ
stain
nonneoplast
popul
although
visual
inspect
normal
popul
commonli
use
subject
intern
control
object
control
measur
current
place
normal
nkcell
present
peripher
blood
sampl
submit
flow
cytometri
possibl
provid
opportun
develop
object
control
hypothes
normal
nkcell
popul
would
demonstr
distinct
reproduc
stain
pattern
includ
analyz
presenc
nkcell
neoplasm
normal
popul
could
use
follow
flow
cytometri
instrument
perform
time
flow
cytometr
data
review
peripher
blood
specimen
stain
pe
apc
fitc
acquir
fac
cantoii
instrument
peripher
blood
specimen
juli
june
juli
review
well
abnorm
tcell
popul
may
septemb
nkcell
subset
includ
aberr
popul
identifi
use
fac
diva
templat
bd
bioscienc
median
fluoresc
stain
intens
mfi
determin
specimen
n
classifi
abnorm
popul
none
b
cell
cell
mfi
compar
four
popul
cell
bright
bright
naiv
cell
signific
differ
mfi
found
specimen
abnorm
popul
specimen
abnorm
tcell
bcell
popul
eg
specimen
abnorm
popul
vs
abnorm
tcell
popul
vs
p
addit
mfi
specimen
march
septemb
use
plot
move
averag
build
leveyjen
plot
move
averag
demonstr
signific
differ
two
flow
cytometri
instrument
despit
instrument
clone
vs
p
also
highlight
signific
chang
mean
mfi
reloc
laboratori
vs
p
conclus
normal
nkcell
popul
identifi
specimen
could
use
establish
object
intern
control
criteria
even
specimen
aberr
nkcell
popul
normal
tcell
stain
also
use
monitor
longitudin
perform
flow
cytometri
instrument
clinic
laboratori
opensourc
onlin
databas
clinic
patholog
consult
cigdem
himmetoglu
patrick
c
sinan
noah
laboratori
medicin
univers
washington
seattl
wa
corpor
redmond
wa
typic
resid
program
substanti
portion
patient
care
clinic
patholog
servic
take
place
resid
call
laboratori
sinc
issu
handl
resid
typic
record
convent
electron
medic
record
document
educ
valu
oncal
experi
provid
evid
compet
difficult
task
faculti
addit
histor
record
oncal
experi
provid
valuabl
knowledg
base
depart
previous
develop
oncal
databas
system
microsoft
activ
server
page
frontend
microsoft
access
backend
system
approxim
call
enter
june
requir
replac
due
scale
databas
lack
support
outdat
tool
project
rewrit
oncal
databas
use
entir
opensourc
softwar
stack
initi
april
use
apac
web
server
python
web
framework
call
flask
postgresql
databas
instanc
host
depart
server
feder
account
manag
authent
institut
domain
provid
use
pubcooki
hipaacompli
opensourc
databas
offer
interfac
track
incom
call
oncal
resid
new
record
edit
screen
tailor
resid
oncal
workflow
facilit
data
entri
bookmark
fulltext
search
list
view
record
without
phi
print
faculti
review
featur
like
tag
flag
link
databas
entri
comment
vote
multipl
user
privileg
level
allow
deleg
certain
administr
function
trust
user
sinc
new
system
implement
juli
call
entri
defin
tag
call
categori
creat
comment
entri
entri
updat
averag
four
time
survey
conduct
resid
current
use
databas
prove
overal
satisfact
scale
respond
agre
strongli
agre
databas
posit
impact
patient
care
help
improv
test
util
transfer
care
user
cite
automat
search
previou
entri
medic
record
number
auto
save
link
call
public
use
featur
opensourc
effect
softwar
secur
platform
laboratori
medicin
depart
aim
onlin
track
case
posit
impact
resid
educ
patient
care
power
featur
maintain
eas
use
simplic
survey
microbiolog
laboratori
technologist
continu
educ
present
patholog
resid
thoma
mcdonald
sponsor
richard
haspel
beth
israel
deaco
medic
center
boston
laboratori
technologist
must
complet
continu
educ
ce
credit
order
maintain
certif
variou
state
nation
agenc
bidmc
patholog
resid
give
live
present
count
ce
credit
laboratori
technologist
present
gener
involv
powerpoint
slide
last
minut
order
learn
technologist
view
present
identifi
way
improv
eightquest
surveymonkey
survey
develop
email
laboratori
technologist
anonym
respons
receiv
individu
result
studi
follow
respond
want
ce
present
everi
week
want
weekli
present
want
monthli
present
topic
ce
present
respond
definit
interest
present
specif
bidmc
patient
receiv
workup
microbiolog
laboratori
popular
topic
specif
diseas
eg
hiv
fundament
microbiolog
eg
antibiot
new
technolog
eg
molecular
test
method
technologist
also
ask
often
work
case
think
would
good
case
ce
present
respons
one
time
everi
two
week
per
month
less
per
month
addit
express
interest
anonym
evalu
present
freetext
respons
includ
sever
comment
indic
prefer
present
focu
clinic
aspect
case
oppos
laboratori
aspect
conclus
studi
follow
respond
gener
favor
ce
present
everi
week
desir
topic
present
specif
bidmc
patient
especi
clinic
aspect
case
addit
major
respond
work
case
least
per
month
think
would
good
case
ce
present
henc
mechan
must
place
wherebi
laboratori
personnel
feel
comfort
commun
interest
case
patholog
resid
attend
final
method
implement
wherebi
laboratori
personnel
anonym
evalu
ce
present
light
result
pilot
studi
survey
question
current
refin
order
elucid
area
ambigu
technologist
prefer
method
evalu
present
enhanc
survey
administ
april
laboratori
differ
size
aim
increas
generaliz
result
increas
reliabl
result
increas
survey
number
clinic
util
calreticulin
mutat
test
diagnosi
nonmut
myeloprolif
neoplasm
idiopath
thrombocytosi
leukocytosi
thrombosi
joshua
r
menk
henrietta
seet
farid
f
chehab
sponsor
enriqu
terraza
depart
laboratori
medicin
univers
california
san
francisco
ca
introduct
somat
mutat
exon
calreticulin
calr
recent
found
approxim
patient
nonmut
myeloprolif
neoplasm
mpn
includ
primari
myelofibrosi
pmf
essenti
thrombocythemia
et
associ
low
risk
thrombosi
rel
mutat
diseas
two
common
calr
mutat
type
delet
type
ii
insert
correl
diagnosi
pmf
et
respect
howev
clinic
util
calr
mutat
test
diagnosi
mpn
idiopath
thrombocytosi
leukocytosi
thrombosi
defin
method
archiv
peripher
blood
bone
marrow
dna
sampl
suspect
pmf
et
idiopath
thrombocytosi
leukocytosi
thrombosi
neg
retriev
molecular
diagnost
laboratori
singl
institut
clinic
diagnos
bone
marrow
biopsi
report
patient
review
diagnosi
confirm
criteria
primer
bracket
exon
calr
gene
use
amplifi
region
encompass
previous
report
mutat
result
pcr
product
analyz
capillari
electrophoresi
size
determin
dna
marker
result
eighteen
patient
nonmut
mpn
show
mutat
calr
calr
mutat
includ
eight
type
mutat
six
type
ii
mutat
four
previous
undescrib
insertionsdelet
calr
mutat
patient
show
mix
allel
burden
one
patient
progress
et
calr
type
ii
mutat
load
evolv
nearli
clonal
mutat
chemotherapi
type
calr
mutat
found
five
patient
pmf
two
patient
et
type
ii
calr
mutat
found
six
patient
et
one
patient
pmf
two
case
posit
calr
mutat
test
establish
diagnosi
mpn
thrombocytosi
consid
reactiv
none
patient
histori
idiopath
leukocytosi
thrombosi
show
calr
mutat
conclus
mutat
calr
clinic
use
confirm
diagnosi
mpn
includ
case
thrombocytosi
unclear
etiolog
calr
mutat
type
type
ii
correl
diagnosi
pmf
et
respect
case
may
help
reclassifi
case
bone
marrow
find
could
repres
either
prefibrot
pmf
et
calr
mutat
test
recommend
patient
idiopath
leukocytosi
thrombosi
low
likelihood
find
calr
mutat
cohort
deriv
silico
standard
curv
maxim
number
sampl
bcrabl
qpcr
run
cml
patient
monitor
minim
residu
diseas
justin
mak
martha
gunthorp
farid
chehab
sponsor
deborah
french
depart
laboratori
medicin
univers
california
san
francisco
ca
quantit
analysi
transcript
consider
prognost
valu
minim
residu
diseas
monitor
chronic
myelogen
leukemia
cml
realtim
pcr
qpcr
method
choic
determin
ratio
requir
two
standard
curv
one
anoth
intern
control
typic
standard
curv
gener
triplic
cdna
respect
log
dilut
posit
cell
line
neg
cell
line
thu
limit
number
well
dedic
patient
sampl
evalu
use
silico
standard
curv
use
ratio
gener
independ
standard
curv
run
carri
quantstudio
qpcr
platform
life
technolog
cycl
threshold
ct
valu
averag
cdna
dilut
run
use
gener
silico
standard
curv
reveal
regress
coeffici
respect
linear
regress
equat
standard
curv
use
determin
ratio
individu
ratio
previous
determin
tradit
standard
curv
comparison
tradit
silico
ratio
log
show
overal
correl
coeffici
import
ratio
remain
log
interv
sinc
minim
residu
diseas
evalu
base
log
chang
cours
kinas
inhibitor
treatment
result
ensur
reliabl
silico
standard
curv
determin
accur
ratio
goal
maxim
patient
sampl
per
run
routin
implement
approach
would
still
requir
tradit
standard
curv
run
month
confirm
continu
fall
within
rang
silico
standard
curv
overal
abil
doubl
patient
sampl
per
assay
increas
turnaround
time
decreas
cost
minim
technic
labor
immunophenotyp
phenogram
facilit
rapid
interpret
leukemia
lymphoma
multiparamet
immunophenotyp
assay
allen
w
bryan
jr
german
pihan
sponsor
richard
haspel
depart
patholog
beth
israel
deaco
medic
center
boston
multiparamet
flow
cytometri
assay
integr
diagnosi
classif
leukemia
lymphoma
l
l
specif
attribut
mani
l
l
form
increasingli
recogn
help
rapid
diagnosi
often
predict
drive
mutat
disord
howev
typic
numer
display
phenotyp
strip
data
stain
intens
coexpress
pattern
often
convey
import
diagnost
prognost
inform
visual
tool
concis
intuit
display
inform
could
therefor
aid
l
l
diagnosi
facilit
visual
recognit
recal
informationdens
specif
multiparamet
immunophenotyp
develop
intuit
visual
tool
base
implement
simpl
algorithm
routin
integr
averag
clinic
cytometri
laboratori
central
tool
interact
circular
plot
display
presenceabs
express
intens
multipl
l
l
antigen
marker
arrang
circumferenti
sector
denot
stereotyp
cell
type
stem
cell
b
cell
cell
nk
cell
myeloid
cell
radial
codisplay
marker
intens
permit
succinct
assess
overal
express
pattern
like
diagnost
entiti
phenogram
produc
manual
data
entri
autom
convers
fc
file
use
applicationspecif
algorithm
found
effect
convey
express
pattern
clinician
traine
minim
train
requir
immunophenotyp
phenogram
repres
simpl
effect
way
visual
summar
flow
cytometri
assay
suitabl
train
naiv
advanc
cytometri
practition
readili
recogn
pattern
flow
cytometri
data
thu
enhanc
capabl
busi
flow
cytometri
laboratori
thrombincontain
rapid
serum
tube
remov
fibrinogen
band
serum
protein
electrophoresi
nabiha
huq
monica
b
mark
h
wener
sponsor
mark
laboratori
medicin
univers
washington
seattl
wa
sound
blood
center
seattl
wa
serum
protein
electrophoresi
key
part
screen
monoclon
gammopathi
fibrinogen
may
present
contamin
poorli
clot
serum
sampl
may
mistaken
monoclon
protein
spike
region
may
mask
true
monoclon
immunoglobulin
spike
fibrinogen
serum
sampl
commonli
found
patient
anticoagul
therapi
indwel
cathet
kept
open
lowdos
heparin
howev
also
found
patient
coagul
disord
dysfibrinogenemia
liver
diseas
sever
method
previous
describ
distinguish
fibrinogen
band
true
monoclon
spike
includ
remov
fibrinogen
use
protamin
sulfatethrombin
ethanol
precipit
immunofix
antifibrinogen
antibodi
demonstr
presenc
fibrinogen
determin
ratio
show
thrombin
treatment
fibrinogencontamin
serum
sampl
becton
dickinson
bd
vacutain
rapid
serum
tube
rst
conveni
rapid
effect
method
remov
suspect
fibrinogen
band
reveal
underli
monoclon
spike
bd
vacutain
rst
contain
thrombinbas
clot
agent
formul
clot
whole
blood
within
minut
collect
remov
suspect
fibrinogen
serum
plasma
place
rst
invert
incub
minut
room
temperatur
specimen
spun
minut
rpm
protein
electrophoresi
repeat
treat
specimen
treatment
nine
plasma
sampl
method
complet
remov
fibrinogen
peak
eight
nine
specimen
one
specimen
contain
mgdl
fibrinogen
small
residu
fibrinogen
band
thrombin
treatment
pair
test
analysi
monoclon
peak
quantif
thrombintr
plasma
serum
sampl
reveal
differ
quantif
sampl
without
thrombin
treatment
p
thrombincontain
rapid
serum
tube
provid
rapid
conveni
effect
method
elimin
fibrinogen
poorli
clot
serum
specimen
use
tube
alter
quantif
monoclon
compon
serum
protein
electrophoresi
target
sequenc
specimen
limit
dna
microfluidicscoupl
ng
platform
solid
tumor
diagnost
andrew
c
matthew
christin
teresa
jon
sophia
bharat
laboratori
medicin
patholog
supercomput
institut
health
servic
univers
minnesota
health
minneapoli
mn
nextgener
sequenc
technolog
enabl
simultan
detect
mani
genom
alter
hamper
specimen
limit
yield
doublestrand
dna
cytolog
biopsi
formalinfix
paraffin
embed
ffpe
tissu
develop
oncolog
sequenc
panel
accur
test
low
dna
input
specimen
costeffect
rapidli
adapt
manner
panel
cover
hotspot
mutat
gene
util
pcr
amplicon
produc
integr
microfluid
chip
ifc
ffpe
specimen
subject
preliminari
quantit
pcr
qc
step
rule
excess
degrad
dna
specimen
pool
sequenc
miseq
platform
investig
assay
perform
low
dna
input
quantiti
cytolog
ffpe
specimen
rang
ng
ng
respect
compar
replic
sampl
load
higher
dna
quantiti
ng
cytolog
ng
ffpe
uniform
coverag
reproduc
variant
call
two
major
factor
impact
accuraci
assay
low
dna
input
level
averag
coverag
decept
reassur
low
input
level
cytolog
ffpe
respect
significantli
differ
averag
coverag
achiev
higher
dna
quantiti
respect
howev
amplicon
lowinput
specimen
drop
averag
coverag
vs
amplicon
higher
dna
input
total
number
variant
call
increas
cytolog
ffpe
low
dna
input
sampl
compar
replic
higher
input
also
poor
concord
observ
replic
within
low
dna
input
rang
respect
minimum
input
cytolog
specimen
demonstr
concord
ffpe
specimen
demonstr
concord
across
sequenc
base
variant
detect
variant
allel
frequenc
vaf
hotspot
locat
detect
known
mutat
show
sensit
falseposit
rate
vaf
limit
detect
experi
util
preamplif
improv
accuraci
decreas
minimum
dna
input
ongo
data
indic
target
sequenc
use
pcrbase
microfluid
platform
provid
accur
result
reason
vaf
threshold
challeng
clinic
specimen
manag
emerg
depart
addon
laboratori
order
emili
l
ryan
ross
j
molinaro
depart
patholog
laboratori
medicin
emori
univers
school
medicin
atlanta
ga
laboratori
test
order
place
specimen
initi
order
place
tax
resourc
impact
report
delay
may
impact
patient
care
addedon
order
disrupt
normal
workflow
also
impact
staf
need
examin
day
emerg
depart
ed
order
total
two
institut
explor
differ
initi
order
pattern
addon
order
determin
autom
storag
laboratori
process
could
decreas
delay
laboratori
addon
order
chemistri
test
follow
three
test
total
addon
order
troponin
magnesium
lipas
three
test
assess
time
result
initi
order
addon
order
time
result
initi
order
defin
time
specimen
receipt
result
sent
electron
time
result
addon
order
defin
time
order
electron
place
result
sent
electron
sinc
specimen
alreadi
receiv
addon
order
significantli
delay
three
instanc
one
institut
refriger
storag
autom
line
hospit
second
institut
sampl
storag
offlin
hospit
determin
storag
attach
autom
line
reduc
time
result
addon
order
troponin
offlin
test
institut
differ
observ
magnesium
lipas
onlin
test
addit
delay
result
report
addon
sampl
storag
offlin
magnesium
median
time
result
hospit
hour
iqr
hospit
hour
iqr
p
second
approach
improv
addon
time
result
costbenefit
analysi
ad
magnesium
comprehens
metabol
panel
report
result
instanc
order
depend
institut
estim
month
unbil
result
would
incur
order
elimin
approxim
delay
result
report
could
lead
decreas
ed
stay
assess
addit
autom
storag
optim
approach
decreas
report
delay
addon
test
order
geograph
distribut
hphv
genotyp
minnesota
omar
jason
sophia
andrew
shabnam
maria
matthew
jon
shalini
bharat
laboratori
medicin
patholog
epidemiolog
commun
health
univers
minnesota
minneapoli
mn
minnesota
medic
center
fairview
mn
although
one
previou
studi
demonstr
geograph
differ
distribut
hpv
genotyp
differ
geograph
distribut
hpv
genotyp
demonstr
unit
state
given
limit
uptak
hpv
vaccin
identif
region
higher
preval
highrisk
hpv
type
may
allow
alloc
greater
resourc
toward
area
extract
hpv
inform
presenc
hpv
infect
hpv
genotyp
residenti
zip
code
medic
record
women
underw
screen
cervic
cancer
use
pap
smear
hpv
test
univers
minnesota
medic
center
fairview
januari
decemb
hpv
test
perform
use
pcrbase
method
amplifi
region
use
primer
set
follow
tripl
restrict
enzym
digest
use
psti
rsai
haeiii
identifi
hpv
genotyp
exclud
women
multipl
hpv
infect
n
miss
zip
code
inform
n
area
fewer
women
test
n
evalu
geograph
distribut
hpv
genotyp
counti
use
esri
arcgi
desktop
softwar
geograph
boundari
file
nation
histor
geograph
inform
system
wwwnhgisorg
overal
preval
hpv
infect
hpv
genotyp
preval
highrisk
vaccineprevent
hpv
infect
hrhpv
report
previou
studi
preval
hpv
genotyp
hrhpv
higher
among
younger
women
age
year
respect
compar
women
year
age
respect
p
observ
wide
geograph
variat
preval
hpv
infect
hrhpv
goodhu
counti
show
highest
preval
hpv
infect
hrhpv
infect
benton
kanabec
wright
counti
show
lowest
preval
hpv
hrhpv
infect
p
first
studi
identifi
specif
geograph
area
higher
preval
vaccineprevent
hpv
infect
futur
studi
repres
overal
popul
need
replic
find
identifi
area
target
campaign
improv
hpv
vaccin
rate
clinic
patholog
intervent
improv
rate
heparin
anticoagul
grant
p
matt
thoma
r
ron
patti
laura
marisa
b
depart
univers
alabama
birmingham
birmingham
al
unfraction
heparin
ufh
remain
mainstay
treatment
acut
thrombosi
hospit
patient
due
inher
properti
ufh
use
must
monitor
ensur
therapeut
anticoagul
follow
repeat
observ
partial
thromboplastin
time
ptt
agre
antixa
result
undertook
prospect
sidebysid
comparison
two
assay
result
practic
chang
describ
work
multidisciplinari
group
three
need
phase
optim
ufh
therapi
period
baselin
apriljuli
ptt
use
monitor
ufh
period
began
pharmaci
protocol
renam
improv
likelihood
physician
choos
correct
dose
ufh
period
began
replac
ptt
antixa
assay
monitor
ufh
period
calcul
sever
variabl
baselin
patient
antixa
least
uml
therapeut
rang
uml
averag
hour
start
ufh
infus
compar
hour
hour
period
respect
p
overal
end
period
realiz
patient
start
ufh
infus
without
bolu
soft
protocol
indic
treatment
venou
arteri
thrombosi
point
ufh
protocol
renam
intent
dvtpe
cardiac
ob
complianc
correct
dose
improv
furthermor
period
ptt
antixa
run
concurr
ptt
agre
antixa
time
remaind
fals
low
fals
high
similar
rate
comparison
two
assay
p
disagr
base
data
follow
hospitalwid
campaign
stop
use
ptt
replac
antixa
routin
ufh
monitor
describ
percentag
patient
anticoagul
hour
start
ufh
infus
increas
period
period
across
period
mean
age
sd
patient
year
respect
p
median
length
stay
p
inhospit
mortal
p
differ
conclud
clinic
laboratori
collabor
pharmaci
updat
ufh
protocol
educ
campaign
institut
antixa
assay
test
choic
monitor
ufh
improv
outcom
significantli
higher
percentag
patient
fulli
anticoagul
hour
massiv
transfus
protocol
initi
caus
increas
plasma
usag
level
trauma
center
awai
lanc
william
marisa
b
depart
univers
alabama
birmingham
birmingham
al
plasma
clear
indic
massiv
hemorrhag
thrombot
thrombocytopen
purpura
ttp
benefit
remain
unproven
indic
prevent
bleed
prior
bedsid
intervent
optim
use
blood
compon
current
focu
transfus
medicin
reduct
util
red
blood
cell
primari
goal
institut
also
observ
overal
decreas
plasma
transfus
last
year
purpos
studi
analyz
mani
plasma
unit
transfus
servic
line
traumaburn
surgic
nonsurg
specialti
compar
especi
sinc
initi
massiv
transfus
protocol
mtp
mtp
contain
six
red
blood
cell
unit
four
unit
plasma
primarili
util
traumainduc
massiv
hemorrhag
use
transfus
servic
comput
system
collect
data
period
week
month
august
septemb
year
exclud
plasma
given
patient
ttp
total
demand
plasma
decreas
unit
premtp
postmtp
reduc
need
due
fewer
patient
transfus
sinc
averag
number
unitspati
remain
constant
analyz
servic
traumaburn
patient
receiv
highest
mean
number
unit
respect
patient
surgic
specialti
went
unitspati
averag
decreas
pre
postmtp
respect
patient
admit
nonsurg
specialti
contribut
servic
overal
util
show
increas
traumaburn
consist
avail
mtp
surgic
use
decreas
nonsurg
use
remain
similar
analysi
reveal
overal
decreas
plasma
util
due
fewer
unit
indic
patient
combin
patient
nonsurg
condit
receiv
fewer
unitsadmiss
moreov
initi
mtp
result
dramat
increas
overal
usag
plasma
per
patient
especi
traumaburn
group
evalu
effect
previ
color
gram
autom
stain
system
report
posit
blood
cultur
sampl
ari
nowacek
angella
charnotkatsika
sue
boonlayangoor
kathleen
g
beavi
vera
tesic
sponsor
vera
tesic
depart
patholog
univers
chicago
medic
center
chicago
il
sepsi
associ
signific
morbid
mortal
prompt
treatment
appropri
antibiot
crucial
order
achiev
bacteria
grown
blood
cultur
must
accur
identifi
report
first
arguabl
crucial
step
process
gram
stain
gram
stain
vital
tool
character
caus
agent
bacteremia
gram
stain
result
use
physician
immedi
cultur
suscept
result
avail
place
patient
antibiot
like
success
treat
infect
manual
gram
stain
techniqu
effect
use
year
howev
method
limit
number
issu
importantli
result
highli
depend
upon
user
experi
thu
even
standard
procedur
result
still
vari
user
order
reduc
variabl
autom
gram
stainer
develop
util
clinic
microbiolog
laboratori
purpos
studi
evalu
effect
one
model
previ
color
gram
autom
stainer
accuraci
report
gram
stain
posit
blood
cultur
analyz
posit
blood
cultur
time
period
compar
number
correct
report
gener
implement
autom
number
correct
report
significantli
reduc
also
redistribut
type
mistak
made
autom
reduc
type
interpret
error
greatest
decreas
misinterpret
gramposit
bacilli
gramneg
bacilli
howev
autom
increas
misinterpret
rate
bacteria
yeast
overal
data
provid
evid
gram
stain
autom
decreas
variabl
associ
tradit
manual
method
reduc
rate
gram
stain
misinterpret
posit
blood
cultur
turn
improv
clinic
outcom
help
ensur
patient
initi
start
correct
antibiot
infect
improv
accuraci
medic
complianc
determin
signific
reduct
turnaround
time
use
qualit
timeofflight
mass
spectrometri
immunoassaybas
screen
approach
kelli
chantri
frederick
g
patholog
univers
utah
laboratori
salt
lake
ut
institut
clinic
experiment
patholog
salt
lake
citi
ut
convent
approach
pain
manag
complianc
test
util
antibodybas
screen
pointofcollect
poc
cup
rapid
initi
assess
disadvantag
poc
cup
immunoassaybas
screen
includ
low
specif
fals
positivityneg
narrow
detect
profil
within
drug
class
limit
abil
accur
determin
complianc
result
posit
result
typic
requir
confirm
mass
spectrometri
neg
result
often
go
uninvestig
result
ineffici
potenti
incorrect
complianc
determin
studi
complianc
determin
urin
specimen
use
comprehens
hybrid
assay
combin
heterogen
immunoassay
accept
perform
timeofflight
tof
mass
spectrometri
compar
convent
immunoassay
screen
reflex
mass
spectrometri
confirm
workflow
object
compar
inlaboratori
turnaround
time
tat
total
tat
assay
determin
falsenegativeposit
result
immunoassay
screen
resolv
hybrid
assay
demonstr
util
hybrid
assay
provid
qualit
evid
specif
compound
within
drug
class
overal
complianc
assess
anova
post
hoc
analysi
month
patient
result
indic
statist
signific
reduct
mean
analysi
time
hybrid
assay
compar
screen
reflex
inlaboratori
hour
total
time
hour
confirm
alon
hour
inlaboratori
time
hour
total
time
accuraci
complianc
interpret
conduct
residu
urin
specimen
known
prescript
histori
posit
immunoassay
screen
result
subset
sampl
also
analyz
use
nexscreen
poc
cup
perform
nearli
equival
nexscreen
poc
convent
immunoassay
except
three
addit
posit
benzodiazepin
result
identifi
poc
devic
hybrid
assay
superior
confirm
complianc
per
patient
vs
per
prescript
vs
well
identifi
evid
nonprescript
substanc
abus
vs
data
demonstr
util
combin
mass
spectrometri
immunoassay
approach
provid
clinician
method
determin
medic
complianc
substanc
abus
optim
von
willebrand
activ
antigen
ratio
costeffect
method
diagnos
von
willebrand
diseas
abnorm
multim
pattern
children
esther
p
lakshmi
rabia
jun
shuiki
r
depart
immunolog
hematolog
baylor
colleg
medicin
children
hospit
houston
tx
laboratori
diagnosi
von
willebrand
diseas
abnorm
multim
pattern
vwdamp
especi
challeng
due
lack
establish
standard
von
willebrand
factor
activ
antigen
ratio
vwfcofag
trigger
multim
analysi
especi
pediatr
current
publish
guidelin
recommend
vwfcofag
trigger
previous
hospit
standard
practic
use
ristocetin
cofactor
activ
trigger
base
publish
data
antidot
evid
recent
perform
retrospect
studi
demonstr
via
receiv
oper
characterist
analysi
avwfcofag
optim
trigger
vwdamp
sought
examin
effect
implement
new
trigger
term
diagnosi
costeffect
method
perform
retrospect
chart
review
children
vwf
panel
perform
tertiari
hospit
month
pre
postimplement
newli
establish
vwfcofag
trigger
compar
proport
patient
perform
time
period
also
calcul
costeffect
ratio
cer
pre
postimplement
month
addit
compar
cer
determin
trigger
cost
less
per
unit
outcom
correct
diagnosi
vwdamp
result
prior
implement
new
trigger
significantli
higher
proport
patient
perform
compar
postimplement
period
p
preimplement
period
one
patient
confirm
abnorm
significantli
lower
number
postimplement
period
three
patient
confirm
vwdamp
p
costeffect
analysi
show
new
trigger
vwfcofag
cost
per
correct
diagnosi
vwdamp
wherea
old
trigger
cost
per
correct
diagnosi
conclus
diagnosi
vwdamp
children
often
difficult
measur
vwfcofag
key
compon
new
vwfcofag
trigger
result
significantli
fewer
significantli
higher
cer
correct
diagnosi
studi
show
local
establish
datadriven
trigger
result
costeffect
algorithm
approach
diagnos
vwdamp
comparison
minim
residu
diseas
detect
multiparamet
flow
cytometri
pcr
vs
itd
mutat
acut
myeloid
leukemia
jess
manuel
jaso
pei
lin
univers
texa
md
anderson
cancer
center
houston
tx
mutat
gene
occur
patient
acut
myeloid
leukemia
normal
karyotyp
nkaml
nkaml
isol
mutat
good
prognosi
advers
affect
presenc
intern
tandem
duplic
itd
gene
prognost
inform
obtain
assess
respons
initi
chemotherapi
via
measur
minim
residu
diseas
mrd
mrd
measur
immunophenotyp
assess
use
flow
cytometri
fc
pcrbase
detect
mutat
gene
pcrbase
method
gener
sensit
optimum
method
mrd
detect
fulli
establish
search
patient
databas
patient
de
novo
untreat
nkaml
mutat
underw
serial
mrd
monitor
eightcolor
fc
pcr
identifi
patient
seven
men
women
median
age
diagnosi
year
patient
eight
isol
mutat
concurr
itd
mutat
detect
mrd
either
method
time
point
associ
relaps
median
time
relaps
month
patient
neg
mrd
method
underw
relaps
among
group
five
eight
patient
neg
mrd
fc
pcr
first
cours
induct
therapi
howev
three
eight
least
one
sampl
mrd
subsequ
relaps
among
group
nine
patient
neg
mrd
fc
pcr
one
cours
induct
howev
six
least
one
sampl
mrd
follow
relaps
one
patient
discord
result
fc
pcr
persist
mrd
detect
fc
patient
extramedullari
relaps
involv
skin
month
mrdneg
bone
marrow
obtain
one
cycl
chemotherapi
result
show
mrd
measur
fc
pcr
correl
well
nkaml
patient
mutat
without
concurr
itd
mutat
mrd
detect
either
method
correl
impend
relaps
howev
relaps
may
still
occur
includ
extramedullari
site
despit
lack
mrd
addit
result
confirm
major
patient
group
quickli
achiev
mrdneg
statu
induct
slightli
higher
rate
relaps
patient
rare
case
may
show
discord
result
combin
use
method
may
optim
order
practic
util
peripher
blood
smear
rule
hemolysi
daniel
martig
michael
linden
depart
laboratori
medicin
patholog
univers
minnesota
minneapoli
mn
object
institut
tradit
routin
order
numer
peripher
blood
smear
profession
interpret
hematopathologist
typic
clinic
scenario
includ
anem
patient
whose
peripher
blood
sent
review
rule
hemolysi
practic
gold
standard
evalu
anem
patient
quantit
qualit
clinic
laboratori
test
avail
help
evalu
hemolysi
moreov
incid
hemolyt
anemia
rather
low
studi
sought
studi
physician
order
practic
evalu
anemia
includ
hemolysi
well
determin
util
peripher
smear
context
method
review
pertin
clinic
laboratori
data
correspond
peripher
smear
sent
divis
morpholog
review
decemb
select
chart
review
perform
indic
result
select
time
period
blood
smear
correspond
patient
femal
male
mean
age
year
rang
day
year
smear
review
mean
hemoglobin
gdl
rang
averag
mcv
fl
rang
mani
case
addit
ancillari
test
perform
includ
reticulocyt
count
total
bilirubin
haptoglobin
ldh
ddimer
fibrinogen
clinic
indic
heterogen
although
mani
order
assess
hemolysi
dic
andor
ttphu
well
anemia
case
one
patient
repres
two
smear
support
clinic
diagnosi
microangiopath
hemolyt
anemia
smear
show
rare
rare
fragment
red
blood
cell
includ
helmet
cell
schistocyt
insuffici
diagnosi
hemolyt
anemia
moreov
smear
fragment
seen
sampl
patient
clinic
suspicion
hemolysi
conclus
peripher
blood
smear
help
guid
diagnost
test
institut
howev
smear
order
parallel
laboratori
test
quantit
test
result
first
often
influenc
clinic
decis
addit
instanc
presenc
rare
red
cell
fragment
seen
smear
support
diagnosi
hemolyt
anemia
base
find
propos
algorithm
smear
review
morpholog
featur
hemolyt
anemia
cbc
clinic
histori
laboratori
data
heighten
pretest
probabl
identifi
variabl
test
util
big
data
veteran
affair
healthcar
system
ronald
g
hauser
cynthia
brandt
sponsor
christoph
tormey
depart
veteran
affair
west
ct
introduct
health
care
qualiti
includ
effect
deliveri
care
mean
deliveri
health
care
origin
scientif
knowledg
provid
idiosyncrasi
propos
metric
calcul
pretest
probabl
ptp
quantifi
util
variabl
suppos
differ
patient
pretest
probabl
diseas
correl
probabl
abnorm
diagnost
test
intuit
patient
visit
subsaharan
africa
higher
probabl
malaria
hermit
canada
therefor
like
malaria
blood
smear
observ
larg
differ
abnorm
rate
provid
sampl
larg
enough
quit
like
provid
test
popul
differ
risk
approach
assess
util
variabl
compar
abnorm
rate
provid
group
veteran
affair
va
hospit
method
began
select
highvolum
test
noninterpret
result
normalabnorm
test
result
extract
va
region
data
warehous
standard
result
normal
abnorm
uniqu
manual
curat
rule
test
result
drop
determin
posit
rate
hospit
geograph
cluster
hospit
group
visn
result
group
two
way
visn
hospit
within
visn
group
member
fewer
test
exclud
result
extract
million
laboratori
result
test
chosen
standard
result
exclud
test
result
group
result
exclud
group
member
fewer
test
left
visn
group
hospit
cluster
within
visn
posit
rate
differ
time
lowest
highest
abnorm
rate
visn
group
four
group
posit
rate
differ
time
visn
comparison
meet
fold
cutoff
often
still
wide
variat
posit
n
posit
n
hospit
within
visn
show
similar
variabl
least
differ
posit
rate
conclus
experi
highlight
widespread
variabl
small
subset
highvolum
test
result
shown
demonstr
differ
posit
rate
previou
case
studi
group
link
differ
abnorm
rate
differenti
popul
diseas
risk
overal
project
employ
simpl
method
identifi
variabl
test
util
effect
overnight
storag
postthaw
viabil
hematopoiet
progenitor
cell
david
r
donna
dian
sponsor
christoph
tormey
laboratori
medicin
stem
cell
center
yale
univers
school
medicin
new
ct
highdos
myeloabl
chemotherapi
follow
autolog
allogen
transplant
hematopoiet
progenitor
cell
hpc
standard
care
treatment
varieti
malign
cryopreserv
autolog
hpc
necessari
allow
administr
chemotherapi
current
standard
guidelin
storag
cell
prior
cryopreserv
includ
optim
cell
concentr
addit
depend
laboratori
workflow
need
send
hpc
center
cryopreserv
may
occur
immedi
collect
follow
overnight
storag
multipl
studi
demonstr
prolong
storag
may
reduc
viabil
stem
cell
lead
prolong
platelet
engraft
part
ongo
process
improv
program
compar
postthaw
cell
viabil
hpc
collect
via
apheresi
hpca
cryopreserv
day
day
apheresi
collect
valid
previous
statist
differ
mean
viabil
hpc
frozen
day
n
vs
follow
day
n
analysi
observ
trend
toward
lower
viabil
increas
cell
concentr
compar
postthaw
viabil
cell
cryopreserv
overnight
storag
differ
concentr
statist
signific
decreas
viabil
frozen
cell
concentr
averag
viabil
sd
vs
frozen
viabil
sd
p
due
larg
variat
viabil
among
differ
patient
next
perform
pair
test
analysi
pair
product
two
collect
donor
frozen
day
one
collect
overnight
storag
differ
collect
pair
analysi
reveal
signific
decreas
viabil
cell
store
overnight
c
storag
storag
p
thu
conclud
postthaw
viabil
improv
product
either
cryopreserv
day
collect
cryopreserv
overnight
storag
cell
concentr
correl
postthaw
viabil
time
engraft
like
dose
viabl
cell
infus
adequ
rapid
engraft
comparison
vancomycinintermedi
vancomycinsensit
staphylococcu
aureu
use
matrixassist
laser
mass
spectrometri
cheryl
mather
april
abbott
susan
butlerwu
sponsor
geoffrey
baird
depart
laboratori
medicin
univers
washington
seattl
wa
vancomycinintermedi
staphylococcu
aureu
visa
infect
associ
higher
risk
treatment
failur
poorer
outcom
compar
vancomycinsensit
aureu
vssa
goal
studi
therefor
assess
whether
matrixassist
laser
flight
mass
spectrometri
malditof
ms
could
use
distinguish
visa
vssa
isol
base
differenti
protein
express
pattern
twentythre
aureu
isol
visa
mic
vssa
mic
grown
varieti
routin
cultur
media
without
vancomycin
subject
analysi
malditof
ms
presenc
absenc
protein
peak
averag
intens
peak
determin
isol
repeatedli
sampl
blood
agar
littl
differ
two
group
regard
presenc
absenc
peak
express
pattern
howev
vancomycin
present
blood
agar
found
one
peak
uniqu
vssa
isol
furthermor
express
pattern
also
demonstr
signific
differ
three
vssa
peak
present
intens
overexpress
compar
visa
isol
use
muellerhinton
mh
agar
vancomycin
found
addit
signific
differ
presenc
peak
well
express
pattern
nine
peak
overexpress
visa
two
peak
overexpress
vssa
isol
use
support
vector
machin
analysi
abl
correctli
classifi
visa
vssa
isol
mh
agar
use
minimum
four
vssa
five
visa
isol
train
therefor
conclud
differ
visa
vssa
isol
appreci
malditof
ms
inclus
primari
media
contain
low
concentr
vancomycin
follow
malditof
ms
analysi
may
provid
clinic
use
way
identifi
vancomycinintermedi
aureu
time
fashion
routin
method
